

FILED
KITSAP COUNTY CLERK
2013 JAN 25 PM 4:25
DAVID W. PETERSON

ORIGINAL

HONORABLE JAY B. ROOF
Hearing Date: February 5, 2013
Hearing Time: 9:00 a.m.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

IN THE SUPERIOR COURT OF THE STATE OF WASHINGTON
IN AND FOR THE COUNTY OF KITSAP

JOSETTE TAYLOR as Personal
Representative of the Estate of FRED E.
TAYLOR, deceased; and on behalf of the
Estate of FRED E. TAYLOR; and JOSETTE
TAYLOR, Individually,

Plaintiffs

v.

SCOTT BILDSTEN, D.O., individually, JOHN C.
HEDGES, M.D., individually, KITSAP
UROLOGY ASSOCIATES, P.C., a Washington
active, for profit corporation, and INTUITIVE
SURGICAL, INC., a foreign corporation doing
business in Washington,

Defendants.

NO. 09-2-03136-5

PLAINTIFF'S OPPOSITION TO
INTUITIVE'S MOTION FOR
SUMMARY JUDGMENT ON ALL
CLAIMS

I. CASE OVERVIEW

Fred Taylor was severely injured during an operation to remove his prostate gland. This operation is called a prostatectomy. Fred Taylor's operation was the first time his surgeon, Scott Bildsten, had used the da Vinci robotic system, unsupervised, to effectuate a prostatectomy. The robotic system was manufactured by ISI; Dr. Bildsten was trained in its use by ISI.

PLAINTIFF'S OPPOSITION TO ISI MOTION FOR
SUMMARY JUDGEMENT ON ALL CLAIMS

FRIEDMAN | RUBIN
1126 HIGHLAND AVE.
BREMERTON, WA 98312
PHONE (360) 782-4300
FACSIMILE (360) 782-4358

302
[Signature]

1 Like all tort cases, this one involves questions of duty, breach, causation and damages.
2 Because Mrs. Taylor can show genuine issues of material fact as to each element of her claims,
3 ISI's motion for summary judgment should be denied.

4 **A. Duty**

5 A defendant's duty can arise from multiple sources, including statutes and the common
6 law. Here, there is no dispute that the Washington Product Liability Act ("WPLA") imposes
7 certain duties on ISI, as the manufacturer of a product, as a matter of law. *See* RCW 7.72.030.

8 There is a fact question as to whether ISI voluntarily assumed additional duties, beyond
9 the scope of the WPLA, by creating a training program which surgeons could pay to attend
10 whether or not they or their institution had purchased a *da Vinci* robot. Washington law
11 recognizes that a defendant can voluntarily assume duties, beyond those that would otherwise be
12 imposed by law. *E.g. Meneely v. S.R. Smith, Inc.*, 101 Wn.App. 845, 856; 5 P.3d 49, 55 (2000)
13 (trade association that voluntarily undertook to issue safety standards for the protection of pool
14 users, assumed the duty to act with reasonable care); Restatement (Second) of Torts, Section
15 324A.

16 ISI says it did not assume a duty to train doctors. Yet, it admits that it provides each
17 urologist it trains¹ with a document entitled: "The Clinical Pathway and Training Protocol for
18 *da Vinci* Prostatectomy."² Dr. Bildsten was given such a document before he ever operated on
19 a live patient.³ The document describes a detailed training program, telling Dr. Bildsten:

20 The following clinical pathway has been put in place *to ensure success in*
21 *becoming a proficient robotic surgeon.*

22 ¹ Exhibit A to Mullenix Declaration (Daniels Deposition) at 231:23-25 ("Q. Were there ever
times when you didn't go over the clinical pathway with a surgeon? A. No.").

23 ² PT-42, Ex. A.

³ Exhibit PT-42, at 2.

1 (emphasis added).

2 After describing a detailed training regime, designed, operated and controlled by ISI, the
3 document then requires signature from the doctor, committing to the ISI training “pathway,” in
4 order to “*ensure* early success for Robotic Prostatectomy.”⁴ Damon Daniels, the ISI sales rep
5 who gave Dr. Bildsten the Clinical Pathway, admitted that he would tell the surgeons, and wanted
6 those surgeons to believe, that the Clinical Pathway would ensure the surgeon’s success in
7 becoming a proficient robotic surgeon.⁵

8 When training its salespeople, ISI defines this Clinical Pathway document as a
9 “[p]rescribed, stepwise approach for surgeons and OR staff to develop knowledge and skills
10 using the da Vinci Surgical System *in clinical applications*.”⁶ In fact, the “Clinical Sales
11 Representatives” (CSRs) understood that an ISI certification meant the surgeons had
12 successfully completed “the protocol for their specialty” and were able to apply surgical skills
13 “to procedural applications.”⁷ CSRs were explicitly told: “All necessary training for surgeons
14 and nurses is built into the clinical plan.”⁸ In documents it gave to Harrison, ISI urged
15 surgeons to “Follow the Prescribed Clinical Pathway.”⁹

16 As outlined in following sections of this brief, there are a great many additional facts
17 showing ISI’s assumption of the duty to train Dr. Bildsten. But the facts recited above are
18 sufficient to defeat ISI’s summary judgment motion. By “prescribing” and providing a
19

20 ⁴ Exhibit PT-42, at 6 (emphasis added).

⁵ Exhibit A to Mullenix Declaration (Daniels Deposition) at 268:22-269:5.

21 ⁶ PT 212 (emphasis added); Exhibit A to Mullenix Declaration (Daniels Deposition) at 258:10-
22 22; 211:17-18 (“I told [surgeons] ... here’s our clinical pathway document, you know, you
should abide by this”).

⁷ Exhibit A to Mullenix Declaration (Daniels Deposition) at 266:1-8.

23 ⁸ PT-30 at 10878; Exhibit B to Mullenix Declaration (Nagel Deposition) at 59:10-11.

⁹ PT-72 at 1.

1 detailed training program for surgeons that ISI said would “ensure early success for Robotic
2 Prostatectomy,” ISI assumed a duty beyond those imposed by statute upon manufacturers: *it*
3 *assumed a duty to train with reasonable care.* ISI’s disclaimers to the contrary do nothing
4 more than create a genuine factual dispute as to the assumption of the duty and its scope.

5 **B. Breach**

6 The declaration of William Scott Helton, M.D. states that the ISI training program applied
7 to Dr. Bildsten was

8 incomplete and potentially unsafe... Further, to suggest that any surgeon could be
9 adequately trained to perform any type of major surgery using the da Vinci surgical
10 system after only the level of training proposed is unfounded and unsupported by
any data, a leap of faith, potentially unsafe, and irresponsible.”¹⁰

11 While more facts showing ISI’s breach of its assumed duty to train are outlined in later
12 sections of this brief, this declaration, standing alone, is sufficient to defeat ISI’s motion with
13 respect to breach of the duty to train.

14 Under the WPLA, ISI had the same duties all manufacturers do; it can be held liable if
15 it provided a product that was “not reasonably safe because adequate warnings or instructions
16 were not provided.” RCW 7.72.030(1). For example,

17 A product is not reasonably safe because adequate warnings or instructions were
18 not provided after the product was manufactured where a manufacturer learned or
19 where a reasonably prudent manufacturer should have learned about a danger
20 connected with the product after it was manufactured. In such a case, the
21 manufacturer is under a duty to act with regard to issuing warnings or instructions
concerning the danger in the manner that a reasonably prudent manufacturer would
act in the same or similar circumstances. This duty is satisfied if the manufacturer
exercises reasonable care to inform product users.

22 RCW 7.72.030(1)(c); *see also* RCW 7.72.030(1)(b) (describing duty of manufacturers to

23 ¹⁰ Helton Declaration at ¶ 7.

1 provide adequate warnings and instructions with product).

2 In his declaration, Dr. Helton addresses the fact that ISI knew or should have known
3 that Dr. Bildsten would not be in a position to safely perform robotic prostatectomies until he
4 had far more than the 2 proctored surgeries laid out for him by ISI in his Clinical Pathway. He
5 then states:

6 15. For these reasons, ISI had an ethical responsibility to inform Dr. Bildsten
7 that it would likely take him 20 to 40 procedures before he could safely perform
8 unsupervised da Vinci prostatectomy on the average patient, and 50 procedures
9 before he could safely perform unsupervised da Vinci prostatectomy on a patient
10 like Fred Taylor who was not an ideal robotic surgical candidate, especially for a
11 novice surgeon on the robot. ISI should have given these warnings to Dr.
12 Bildsten well before they convinced him to "commit" to their "Clinical
13 Pathway." (These learning curve expectations should have been incorporated
14 into the "Clinical Pathway" drafted by ISI for Dr. Bildsten.) ISI should also have
15 given warnings of this nature to Harrison Medical Center.

16 16. Based on the clinical pathway document that ISI provided to Dr. Bildsten
17 (PT-42), ISI suggested to Dr. Bildsten that he would be safe to operate on
18 patients without supervision after only two proctored surgeries. Rather than
19 telling him that the median time for even high-volume surgeons was 20 to 40
20 procedures for basic proficiency, ISI merely told Dr. Bildsten that he might not
21 "reach a level of comfort" until "around 20" (106-107) procedures. If indeed he
22 was told that, such a statement would be misleading in light of the literature cited
23 above, about which ISI, as a reasonably prudent medical device manufacturer
knew or should have known.^[11]

Dr. Helton concludes his declaration:

20. In light of the facts outlined above, a reasonable and responsible company in
ISI's position would have informed Dr. Bildsten and Harrison Hospital of the
variable and unknown learning curve for robotic prostatectomies for any given
urologist. It would not have encouraged Harrison and Dr. Bildsten to believe
that Dr. Bildsten could safely operate unsupervised after having only completed
its simplified training program (unapproved by the FDA) and two proctored
surgeries. ISI's actions in this regard were irresponsible and reckless.^[12]

While there are many more facts recited below that demonstrate ISI's breach of its duties under

¹¹ Helton Declaration, at ¶¶ 15-16.

¹² Helton Declaration, at ¶ 20.

1 the WPLA to provide adequate warnings and instructions, Dr. Helton's declaration, standing
2 alone, is sufficient to defeat summary judgment.

3 **C. Causation**

4 As recounted by Joseph D. Schmidt, M.D., Dr. Bildsten made numerous mistakes during
5 the Taylor surgery. According to Schmidt, it was a mistake for Bildsten to use the da Vinci at all
6 on Mr. Taylor.¹³ Schmidt also testified that Bildsten fell below the standard of care in failing to
7 create a watertight anastomosis (seal) between the bladder and the urethra, once the prostate was
8 removed.¹⁴ Inflating Mr. Taylor's abdomen with carbon dioxide pressure ("insufflation") at 20
9 mm for the length of time Dr. Bildsten did also fell below the standard of care.¹⁵

10 S. Adam Ramin, M.D. is a robotic surgeon who testified that Dr. Bildsten fell below the
11 standard of care in various ways, including poor patient selection, improper insufflation, and
12 failing to even try to obtain a water-tight anastomosis.¹⁶ He testified that it is more likely than not
13 that Mr. Taylor's outcome would have been different if the anastomosis had been water-tight.¹⁷
14 Among other things, he more likely than not would not have had a breakdown of the rectal repair
15 performed as a result of Dr. Bildsten cutting Mr. Taylor's rectum.¹⁸

16 Dr. Schmidt testified that Mr. Taylor suffered injury from the high-pressure insufflation—
17 including encephalopathy and stroke.¹⁹ Dr. Ramin testified that high-pressure insufflation can
18 cause renal failure, decreased cardiac output, acidosis, and increased "end title CO2."²⁰ As Dr.

19
20 ¹³ Exhibit C to Mullenix Declaration (Schmidt Deposition) at 47-48.

21 ¹⁴ Exhibit C to Mullenix Declaration (Schmidt Deposition) at 49 - 52.

22 ¹⁵ Exhibit C to Mullenix Declaration (Schmidt Deposition) at 49-50, 53.

23 ¹⁶ Exhibit D to Mullenix Declaration (Ramin Deposition) at 102-05.

¹⁷ Exhibit D to Mullenix Declaration (Ramin Deposition) at 105.

¹⁸ Exhibit D to Mullenix Declaration (Ramin Deposition) at 105-06.

¹⁹ Exhibit C to Mullenix Declaration (Schmidt Deposition) at 54-55.

²⁰ Exhibit D to Mullenix Declaration (Ramin Deposition) at 108-109.

1 Ramin testified: "These are some of the problems that this patient developed," and "the scenario
2 here points to the intra-abdominal pressure being the main cause."²¹ The presence of these
3 pressures for a very long time, as was the case in the Taylor surgery, significantly increase the
4 chance of developing respiratory and renal complications, which Mr. Taylor suffered.²²

5 These doctors and others have more to say about Dr. Bildsten's mistakes causing injury to
6 Mr. Taylor, but these citations are enough to establish there are genuine issues of fact in that
7 regard.

8 Prior to this surgery, Dr. Bildsten had performed over 100 prostatectomies using the
9 traditional "open" procedure, without a single complication.²³ A jury could reasonably conclude
10 that the mistakes he made in this robotic procedure were a result of the poor training and lack of
11 warnings he received from ISI. Indeed, that is the conclusion Dr. Bildsten has reached:

12 4. ... I was led to believe that ISI training and two proctored surgeries was
13 sufficient to achieve basic competency and safely perform unsupervised robotic
14 surgeries. I was not told by ISI representatives that paid expert consultants to
15 ISI (as well as other researchers) were reporting that basic competency or
16 proficiency were not being obtained until twenty or more operations were
17 complete.

18 5. I relied upon ISI's representatives to give me a fair and accurate picture of
19 ISI's training program and the learning curve.

20 6. Having learned information in FDA documents about the training program,
21 and from other documents about research on the learning curve to obtain basic
22 competency which I did not know at the time I became involved with ISI, I
23 believe I likely would not have agreed to begin training on the robot had I been
24 given this information.

.....

25 8. At the time I committed to receiving one of Harrison Medical Center's free
26 training slots, and thus to begin performing robotic prostatectomies, I was led to
27 believe I would be able to provide equal or better results to my prostatectomy

28 ²¹ Exhibit D to Mullenix Declaration (Ramin Deposition) at 108.

29 ²² Exhibit D to Mullenix Declaration (Ramin Deposition) at 109.

30 ²³ Exhibit Q to Mullenix Declaration (Bildsten Deposition) at 42:21-43:13.

1 patients with the daVinci machine. I was not told by ISI that, especially for
2 surgeons with no prior laparoscopic experience doing prostatectomies, this was
3 very unlikely until I accomplished 100 or more robotic surgeries. Had I been
4 informed of that fact, I would not have performed da Vinci surgery on Fred
5 Taylor.

6 **9. During my robotic surgery training by ISI, I was not informed of the need
7 to ensure a watertight urethral anastomosis. Likewise, I was not informed by
8 ISI of the dangers of insufflating patients during long surgeries at levels over
9 15 millimeters of mercury. Had I been so informed, I would have conducted
10 the Taylor surgery differently, in a way that would have reduced the risk of
11 harm to Mr. Taylor.²⁴**

12 More facts are recited below to establish genuine issues of material fact as to whether
13 ISI's poor training of, and lack of warnings to Dr. Bildsten was a substantial factor in causing
14 Mr. Taylor's injuries; but the facts cited above are independently sufficient to justify denial of
15 ISI's motion.

16 **D. Damages**

17 There is no factual dispute that Mr. Taylor suffered injuries and damages during his
18 operation. The nature and extent of the injuries is in dispute, but is not put in issue by ISI's
19 motion. The portions of the record cited above establish not only causation, but many of the
20 injuries.

21 Because ISI has made such an effort to convince the Court that the rectal injury did not
22 occur during the robotic portion of the operation, plaintiff cites the court to the testimony of
23 Dr. Ramin, which clearly refutes defendant's position:

Q Is it your opinion that it [the rectal injury] occurred during the da
Vinci portion of the procedure before opening?

A Yes.

Q How did that happen?

A This is a portion where they were trying to again develop the

²⁴ Declaration of Dr. Scott Bildsten, at paragraphs 4-6, 8-9 (emphasis added).

1 Denonvillier's fascia. And based on his operative report he said after several
2 hours of trying to develop this area, they decided to convert to open surgery.
3 This is an area which has a high risk of cutting into the rectum and not
4 recognizing it. The rectum is only a few millimeters away from the
5 Denonvilliers' fascia in this particular area. And if you have more visualization,
6 if there is blood coming into the field and bowel is coming into the field, add it to
7 physician's fatigue, add it to a certain level of frustration, and add it to a patient
8 not being in a correct position, it's very hard to tell whether you're properly --
9 you are in the proper space or not. Very high chance that the rectum is injured at
10 that point.^{25]}

11 There are genuine issues of material fact about the damages Mr. Taylor received during
12 surgery, and ISI cannot credibly argue otherwise.

13 E. Summary

14 The facts and law reviewed thus far are sufficient to justify denial of ISI's motion in all
15 respects. If plaintiff was to end the brief here, however, the Court would lack context for ruling
16 on the evidentiary motions that will shortly follow. Rather than force the Court to learn the case
17 in a piece-meal fashion, plaintiff has elected to provide a thorough (though not complete)
18 discussion of how the facts relate to her legal claims. It is hoped that in the long run, this will
19 make the Court's job easier. The expanded legal arguments below should also make the Court's
20 job easier as it considers evidentiary motions and jury instructions.

21 II. STATEMENT OF FACTS

22 A. ISI is founded to pursue military-developed robotic surgery technology.


23 In 1994, Dr. Fred Moll learned of a robotic "tele-surgery" system developed at Stanford
24 Research Institute in California and funded by the army.²⁶ The original goal of the project was

25 Exhibit D to Mullenix Declaration (Ramin Deposition) at 79:10-80:3.

26 PT-240 ("Has the Real MIS Revolution Finally Arrived") at 2235.

1 to make it possible for surgeons to operate on wounded soldiers from secure locations.²⁷ Moll
2 bought a license for the technology and founded Intuitive Surgical, Inc. ("ISI"), in 1995.²⁸ ISI's
3 only corporate offices in the United States are in Sunnyvale, California.²⁹ ISI also
4 manufactures its robots in Sunnyvale.³⁰

5 The ISI robot allows a surgeon working through a console to use to use remote-
6 controlled instruments inside the body, as shown in the following schematic:³¹



SOURCE: Intuitive Surgical

[32]

13
14 Moll described this system in 1997 as "a new approach to minimally invasive surgery."³³

15 **B. In response to specific and explicit concern from the Food and Drug**
16 **Administration, ISI promises to provide comprehensive training, objective**
17 **assessment, and certification for would-be robotic surgical teams.**

18 The novelty of ISI's surgical approach posed a hurdle in that the robot could not even
19 be legally *advertised* in the United States when ISI began. ISI first sought permission to

20 ²⁷ PT-240 ("Has the Real MIS Revolution Finally Arrived") at 2235.

21 ²⁸ PT-240 ("Has the Real MIS Revolution Finally Arrived") at 2233 (founded ISI in 1995),
22 2235 (licensed technology).

23 ²⁹ Exhibit B to Mullenix Declaration (Nagel Deposition) at 15:23-16:2. ISI's original offices
were in Mountain View, California. It now also maintains an office in Switzerland.

³⁰ Mullenix Declaration at ¶ 4 (Ryan Rhodes testified that robots manufactured in California).

³¹ PT-240 ("Has the Real MIS Revolution Finally Arrived") at 2236.

³² PT-240 ("Has the Real MIS Revolution Finally Arrived") at 2237.

³³ PT-240 ("Has the Real MIS Revolution Finally Arrived") at 2233 (1997); 2236 ("new
approach").

1 advertise from the FDA in 1996.³⁴ The initial request sought permission only to market the
2 device “to perform blunt dissection and to manipulate tissue, but nothing beyond that.”³⁵ In
3 other words, ISI’s first request “included only instruments providing surgical assistance *i.e.*,
4 retractors and graspers, rather than tools to perform surgical tasks, *i.e.*, scissors and cautery.”³⁶
5 However, even for these basic functions, ISI assured the FDA that it would provide *training* for
6 surgeons who would use the device.³⁷ The draft labeling that ISI provided to the FDA stated
7 explicitly: “Appropriate training and instructions will be provided to ensure that the surgeon is
8 sufficiently familiar with operation of the System to be able to effectively perform the desired
9 surgical procedures.”³⁸ The device was cleared for this limited purpose, with this
10 understanding of “appropriate training,” on July 31, 1997.

11 Even so, by January 1999,³⁹ ISI had still not sold a single robot⁴⁰ or trained a single
12 surgeon in the US.⁴¹ Accordingly, ISI sought to drastically expand the manner in which it
13 could permissibly market its robot. In pursuit of this goal, ISI filed a new application with the
14 FDA seeking clearance to market its robot for certain kinds of laparoscopic surgical
15 procedures: “cholecystectomy” and “Nissen fundoplication.”⁴²

17
18 ³⁴ PT-242 (K965001 Cover Sheet) at 25599.

19 ³⁵ Exhibit E to Mullenix Declaration (Kreaden Transcript) at 14:9-11.

20 ³⁶ PT-145 at 31447; *see also* PT-253(Indications for Use Statement for K965001) at 3167 with
21 PT-235 (Indications for Use Statement for K990144) at 27474.

22 ³⁷ PT-59 at 3137 (providing revised labeling to the FDA “to clarify our intent regarding
23 training”).

³⁸ PT-59 at 3140.

³⁹ PT-241 (ISI Internal Timeline) at 27458, PT-231 (510(k) Summary) at 2706-2708.

⁴⁰ Exhibit E to Mullenix Declaration (Kreaden Deposition) at 72:13-17.

⁴¹ Exhibit E to Mullenix Declaration (Kreaden Deposition) at 72:21-25.

⁴² PT-231 (510(k) Summary) at 2706-2708, 2713. A cholecystectomy is a gall bladder removal
procedure, while a Nissen fundoplication is a surgical procedure to address gastroesophageal
reflux, or GERD.

1 ISI filed this new request under the “Premarket Notification”⁴³ regulatory regime,
2 rather than the more burdensome and rigorous “Premarket Approval”⁴⁴ regulatory regime.
3 Although there are numerous differences between these two regimes, the primary difference is
4 that the manufacturer need demonstrate only “substantial equivalence” to a predicate device
5 under the Premarket Notification regime, whereas the manufacturer must show “safety and
6 efficacy” when seeking PMA Approval.⁴⁵ While the manufacturer makes the initial election
7 between these regimes, the FDA can unilaterally reclassify a proposed technology into the
8 appropriate category once it begins to review the application.

9 On May 19, 1999, the FDA did just that, reclassifying ISI’s device as a “Class III”
10 device, meaning ISI would be required to undergo the more rigorous “PMA” process and
11 receive “approval” for “safety and efficacy.”⁴⁶ On June 16, 1999, ISI presented data in support
12 of its now-PMA application to the Medical Devices Advisory Committee of the FDA’s
13 General and Plastic Surgery Devices Panel.⁴⁷ ISI’s founder, Dr. Fred Moll, personally
14 presented information to the Panel, which asked numerous questions about the learning curve
15 and training plan for surgeons who would use the robot. Dr. Moll assured the Panel that ISI
16 had specific, concrete plans for training on the device:

17 I think in one sense surgeons never have enough training but, clearly, training is
18 a very important part of this story and will be a very important part of how this
19 system is introduced. There is no surgical device that is introduced and is

20 ⁴³ PreMarket Notification is also sometimes referred to as the “510(k)” process, which refers to
21 § 510(k) of the federal Food, Drug and Cosmetic Act, which is now codified at 21 C.F.R. §
22 807.81-807.100.

23 ⁴⁴ “PreMarket Approval” refers to § 515 of the federal Food, Drug and Cosmetic Act, which is
now codified at 21 C.F.R. § 814.1-814.126.

⁴⁵ Exhibit E to Mullenix Declaration (Kreaden Deposition) at 46:19-47:2, 49:8-18.

⁴⁶ PT-236 at 2699; PT-55 (Panel Meeting Transcript) at 34 (“We submitted a 510(k) in January
of this year and last month FDA made the decision to convert that 510(k) to a PMA.”).

⁴⁷ See PT-55.

1 immediately picked up by the surgeon and used properly without training. I
2 won't go into specific plans about how the system, if sold in the United States,
3 will be trained. I am probably not the right person to do that, but it is at the top of
our mind and we will have very clear plans for introducing a training protocol
together with the sale of this device.^{48]}

4 Dr. Moll later added that ISI took training "very seriously," and even regarded training as "one
5 of the keys to both clinical and commercial success."⁴⁹ The Panel advised that the robot was
6 "approvable with conditions."⁵⁰ One of the conditions was training: "The sponsor needs to
7 provide a comprehensive training program for the users of this device."⁵¹ FDA notified ISI of
8 the requirement on September 2, 1999.⁵²

9 On November 26, 1999, ISI filed its proposed labeling and training program with the
10 FDA.⁵³ The ISI employees who handled ISI's communications with and submissions to the
11 FDA regarding training each worked out of ISI's California office,⁵⁴ and the majority of ISI's
12 correspondence with the FDA in general "originated in California."⁵⁵

13 In the November 1999 submission, ISI modified its earlier "indications for use" to
14 indicate that the device was "intended for use by *trained* physicians."⁵⁶ The training program
15 that ISI described to the FDA was intense, objective, and marked by constant "expert"⁵⁷
16 assessment.⁵⁸ ISI stated that "consistent assessment" was one of the "key components" of its
17 training program, a lesson purportedly learned from "the pitfalls" of the "laparoscopic boom of

18 ⁴⁸ PT-55 at 78-79.

19 ⁴⁹ PT-55 at 184.

20 ⁵⁰ PT-100 at 26886-26887.

21 ⁵¹ PT-100 at 26886-26887.

22 ⁵² PT-100 at 26886-26887.

23 ⁵³ PT-6.

⁵⁴ Exhibit E to Mullenix Declaration (Kreaden Deposition) at 34:23-35:5.

⁵⁵ Exhibit E to Mullenix Declaration (Kreaden Deposition) at 38:20-24.

⁵⁶ PT-6 at 799 (emphasis added).

⁵⁷ PT-6 at 815 ("Expert assessment" for Phases Two and Three).

⁵⁸ See PT-6 at 815.

1 the late 1980's and early 1990's."⁵⁹ This assessment would apply to "both cognitive and motor
2 skills competency," and it would occur "throughout the program."⁶⁰ It also meant ISI would
3 "develop and document metrics."⁶¹ ISI proposed that the training would occur "in phases,"
4 and would include "training centers."⁶² The training centers would be required to "utilize
5 standard performance assessment for each phase *prior to moving the learner to the next*
6 *phase*."⁶³ ISI touted the effectiveness of its "phases" approach in its FDA submissions:

7 Each phase accomplished will build the knowledge and skills necessary to
8 prepare the learner to successfully perform his or her role in the recommended
9 operation of the System. Additionally, each phase will allow the instructor and
10 learner to assess knowledge and skills *prior to moving to the next module*. This
11 will provide for the feedback and remediation that are so important in learning
12 new knowledge and skills. [⁶⁴]

13 The first phase would be a "distance learning program"⁶⁵ that would "mimic the
14 cognitive activity required during actual performance."⁶⁶ The program would provide the
15 knowledge "necessary to perform pre-operative System preparations, intra-operative use and
16 preliminary troubleshooting, and post-operative care of the System."⁶⁷ It would also provide "a
17 basic understanding of computer-assisted surgery and the System."⁶⁸ ISI proposed to asses
18 performance with a "70-item, multiple-choice instrument" based on "curriculum learning
19 objectives."⁶⁹ The entire "surgical team" would be required to pass this test.⁷⁰ By the end of

18 ⁵⁹ PT-6 at 814.

19 ⁶⁰ PT-6.

20 ⁶¹ PT-6.

21 ⁶² PT-6.

22 ⁶³ PT-6 (emphasis added).

23 ⁶⁴ PT-6 at 815 (emphasis added).

⁶⁵ PT-6 at 814.

⁶⁶ PT-6 at 817.

⁶⁷ PT-6 at 814.

⁶⁸ PT-6.

⁶⁹ PT-6.

⁷⁰ PT-6.

1 Phase One, ISI promised, among other things, that all surgical team members would be able to
2 “Describe patient positioning and preparation”⁷¹ and all physicians would be able to “Meet
3 team objectives” and “Identify and describe System-specific surgical skills.”⁷²

4 The second phase was to be a “three-day, hands-on program” at an “approved training
5 center.”⁷³ Whereas the first phase was to provide knowledge, the second phase was to provide
6 “the practical skills necessary” for pre-operative preparations, intra-operative use,
7 troubleshooting, and post-operative care of the System.⁷⁴ Because the entire team would
8 attend, the “team” would also “gain a basic understanding of team dynamics necessary for
9 successful use of the System.”⁷⁵ ISI promised that “[p]erformance evaluation will be ongoing
10 within the hands-on training throughout the course,⁷⁶ which would include “constructive
11 simulation of procedures.”⁷⁷ Moreover: “*Expert* evaluation ... will determine mastery.”⁷⁸

12 Phase Three would occur “during installation at the site of the installed System.”⁷⁹ The
13 third phase would use an “installation/in-service training curriculum” to provide each of the
14 above-mentioned skills, teach more advanced troubleshooting skills,⁸⁰ and further guarantee
15 that the team gained “a basic understanding of the team dynamics necessary for successful
16 use.”⁸¹ Also, during this phase, both the “console” and “patient-side” surgeons would
17

18 ⁷¹ PT-6 at 816.

19 ⁷² PT-6.

20 ⁷³ PT-6 at 815.

21 ⁷⁴ PT-6.

22 ⁷⁵ PT-6.

23 ⁷⁶ PT-6.

⁷⁷ PT-6 at 819.

⁷⁸ PT-6 at (emphasis added).

⁷⁹ PT-6 at 815.

⁸⁰ PT-6 at 815.

⁸¹ PT-6 at 815.

1 “advance their surgical skills” through “intense practice on surgical models.”⁸² ISI would also
2 “introduce problem-solving activities during a surgical procedure.”⁸³ Again, ISI promised that
3 “Metrics” would be developed to “certify mastery, including time and accuracy.”⁸⁴ Again, ISI
4 promised that, with respect to the entire team: “Expert evaluation ... will determine mastery.”⁸⁵

5 Phase Four was to be conducted by the team itself as a “self-directed” curriculum.
6 Though this portion was self-directed, ISI still promised that trainee surgeons would “*practice*
7 *specific procedures* on surgical models, including cadaveric models[.]”⁸⁶ Doing so would
8 “result in demonstrated mastery of competence in applying surgical skills to procedural
9 applications.”⁸⁷ This would occur “prior to application of the System to patients[.]”⁸⁸ And ISI
10 promised to monitor the surgeons’ performance during this phase: “Monitoring of performance
11 within the Surgeon Skills Practice to Competence phase training will be ongoing throughout
12 the phase.”⁸⁹ By the end of Phase Four, ISI stated, all physicians would be able to
13 “[d]emonstrate specific surgical skills applied to specific procedures” and even “[d]emonstrate
14 to the Chief of Surgery the necessary competence for credentialing.”⁹⁰ This would be
15 determined by “[e]xpert and peer evaluation” and “successful completion of surgical
16 procedures.”⁹¹

17 ISI also promised, with respect to Phase Four, that that the company would provide the
18

19 ⁸² PT-6 at 815.

20 ⁸³ PT-6 at 821.

21 ⁸⁴ PT-6 at 815.

22 ⁸⁵ PT-6 at 815.

23 ⁸⁶ PT-6 at 815 (emphasis added).

⁸⁷ PT-6 at 815.

⁸⁸ PT-6 at 815.

⁸⁹ PT-6 at 823.

⁹⁰ PT-6 at 822.

⁹¹ PT-6 at 823.

1 names of “experienced preceptors and proctors” that the hospital may access if it is necessary
2 to the credentialing process.⁹² ISI would also provide to hospitals “a training curriculum that
3 can be used for training” for operating room staff and surgeons.⁹³

4 To lend credibility to the training program it proposed, ISI stated that it was partnering
5 with an outside firm to audit and improve its training program:

6 Intuitive Surgical, Inc. is partnering with Medical Education Training Associates
7 (META) to assess learning needs and develop and refine the curriculum in the
8 pilot process. Additionally, META will assess the pilot program's success and
9 design the curriculum, instructional design, and instructional delivery system for
10 both training centers and installation sites. The META organization includes
11 M.Ed. and Ed.D. level personnel who have had extensive experience in
12 instructional design, simulation training, and industry sponsored device
13 training.^[94]

14 ISI included in its materials the curriculum vitae “of the principals” from META whom it
15 proposed to work with.⁹⁵

16 After reviewing ISI’s proposed training program, the FDA responded on February 2,
17 2000, with a “Deficiency” letter.⁹⁶ With respect to the training program, the FDA mandated
18 language changes, asked for definitions of terms used, and demanded that ISI provide the “tool
19 of evaluation and criteria of success” for “each phase of the training.”⁹⁷ The FDA also
20 demanded that ISI produce a copy of the “70-item multiple choice instrument” it intended to
21 use.⁹⁸ The FDA required ISI to provide “additional detail” and discussion about the training

22 ⁹² PT-6 at 815.

23 ⁹³ PT-6 at 815.

⁹⁴ PT-6 at 815.

⁹⁵ PT-6 at 815.

⁹⁶ PT-7 at 765.

⁹⁷ PT-7 at 765.

⁹⁸ PT-7 at 765.

1 and criteria for success in Phases Three and Four.⁹⁹

2 ISI produced its response on February 22, 2000.¹⁰⁰ With respect to Phase One (the
3 distance learning program), ISI assured that a “da Vinci™ System trainer” would perform the
4 evaluation of trainees, and even “provide[] feedback to the surgical team.”¹⁰¹ Likewise, a da
5 Vinci System trainer would perform evaluations for Phases Two, Three, and Four. For Phase
6 Three, ISI promised to “make the assessment data available to each team and the hospital
7 official in charge of the da Vinci™ system training.”¹⁰² For Phase Four, ISI promised that its
8 trainers’ evaluations would be measured “against the [hospital] directed objectives for
9 simulated intra-operative tasks.”¹⁰³ In addition to those hospital-directed objectives, the Phase
10 Four criteria for success would be measured with “the same instruments and evaluation as
11 Phase III training,”¹⁰⁴ “based on the surgical team’s use of the da Vinci™ surgical system as
12 applied during targeted procedure(s).”¹⁰⁵ The evaluations in Phases Two, Three, and Four,
13 would be “quantitatively assessed ... using a Likert-type scale of one to five (1=poor and
14 5=excellent).”¹⁰⁶

15 On May 17, 2000, FDA sent *another* deficiency letter to ISI. This time, the FDA
16 sought copies of the actual “distance learning materials” and “questionnaires” that ISI intended
17 to use.¹⁰⁷ ISI responded the next day by producing its 64-page “comprehensive Training
18
19

20 ⁹⁹ PT-7 at 765.

21 ¹⁰⁰ PT-8 at 2211-2212; PT-246 at 761 (providing date).

22 ¹⁰¹ PT-8 at 2211.

23 ¹⁰² PT-8 at 2214.

¹⁰³ PT-8

¹⁰⁴ PT-8 at 2215.

¹⁰⁵ PT-8 at 2215.

¹⁰⁶ PT-8 at 2211-2212.

¹⁰⁷ PT-10 at 27497.

1 Package.”¹⁰⁸ This training package confirmed that ISI’s “Surgical Training Personnel” would
2 be responsible for “instructional materials and facilitation” of the da Vinci training, meaning
3 they would “Organize and facilitate” the training phases, “Assess performance” of the “da
4 Vinci™ Surgical System gross tasks during training,” “Coordinate proctor(s) as requested,”
5 and “Provide post training support as requested.”¹⁰⁹

6 ISI also provided more detailed information regarding each proposed phase of its
7 training program. For instance, ISI actually provided the 70-item test it would use to assess
8 Phase One performance.¹¹⁰ For Phase Two, ISI listed out 23 different goals and objectives,
9 promising to train on 22 of those goals during the three-day off-site training.¹¹¹ Relevant to
10 this case, that training was to include: (a) “Patient Positioning and Preparation,”¹¹² which
11 would require the trainee to “Describe and demonstrate patient position on table matching OR
12 procedure;”¹¹³ (b) “Secondary troubleshooting,”¹¹⁴ which addressed “Insufflator device
13 operation and settings”¹¹⁵ and required trainees to recognize when the “Position of Position of
14 patient on [the] table [was] incorrect for da Vinci Surgical System procedure;”¹¹⁶ (c) “Surgical
15 skills”, which required the surgeon to “Identify, perform, and evaluate the specific surgical
16
17
18

19 ¹⁰⁸ PT-10 at 27548-27614; PT-10 at 27497 (“comprehensive Training Package”).

20 ¹⁰⁹ PT-10 at 27549.

21 ¹¹⁰ PT-10 at 27554-27569.

22 ¹¹¹ PT-10 at 27572 (day one), 27574 (day two), 27580 (day three). “Anesthesia considerations”
23 was the only goal that ISI did not explicitly promise to train upon in Phase Two. As noted
below, ISI did promise to train on anesthesia considerations in Phase Three. PT-10 at 27591.

¹¹² PT-10

¹¹³ PT-10 at 27605.

¹¹⁴ PT-10 at 27574.

¹¹⁵ PT-10 at 27609.

¹¹⁶ PT-10 at 27609.

1 skills utilized during surgery using the da Vinci Surgical System and a training model,"¹¹⁷ (d)
2 "Interference of Arms, instruments, scopes, masters, and patient anatomy," which would
3 address "body positioning (patient and table)"¹¹⁸ with the surgeon; and (e) "Team Dynamics,"
4 which would require the entire team to be able to "Describe roles and responsibilities of
5 individual team members, pre-procedure, intraoperatively, and post-procedure."¹¹⁹ Each of
6 these skills would be rated, from 1-5 (1 = Beginner, 5 = Expert), by the trainer.¹²⁰

7 ISI also provided a 13-page agenda that would be used for the training.¹²¹ Among the
8 agenda items relevant to this case:

- 9 • A Day 2 lunchtime review of a "Pre-test."
- 10 • 3 tasks related to Patient Positioning and Preparation, including:
11 "Describe and demonstrate patient position on table *matching sample OR*
12 *procedure.*"
- 13 • A two hour and 45 minute session for the entire surgical team in the
14 "Cadaver or Animal Lab" for "LAP CHOLE AND/OR NISSEN". This includes
15 a section called "Lap Chole or Lap Nissen Procedure," which included:
16 "Identify, demonstrate and evaluate Surgical Skills." The lab session was
17 followed by a 45 minute "SURGEON'S Review" session. That review session
18 included a "Surgeon's Self Assessment of Surgical Skills."¹²²
- 19 • Day 3 included, for the entire team, a one hour and 15 minute "Dry Lab"
20 session plus four more hours in the "Animal or Cadaver Lab." That session
21 would include more drilling on patient positioning and preparation and, among
22 other things, another "Lap Chole or Lap Nissen."¹²³ The lab session was to be
23 followed by another 45 minute Surgeon's Review, and another "Self Assessment

18 ¹¹⁷ PT-10 at 27612-27613. These skills included: "Dissection - blunt/sharp; Tissue handling;
19 Ligating; Holding/passing needles; Suturing skills - large and fine; Knot tying - tensioning large
20 and fine' Ambidexterity; Vision - Anatomy identification within field of view/focal length.
21 Identify skill performance differences with 2-D vs. 3-D. Perform and demonstrate non-dominate
22 [sic] hand skills." *Id.*

21 ¹¹⁸ PT-10 at 27614.

22 ¹¹⁹ PT-10 at 27614.

23 ¹²⁰ PT-10 at 27572 (day one), 27574 (day two), 27580 (day three).

¹²¹ PT-10 at 27572-27585.

¹²² PT-10 at 27579.

¹²³ PT-10 at 27583.

1 of Surgical Skills.”¹²⁴

2 Finally, during the lunch break on the third day of the offsite training, the surgical team and
3 expert trainers would “Create On-Site Plan/Agenda for Installation (Phase 3).”¹²⁵ At the end of
4 that day, ISI assured, the entire surgical team would review its “Workshop Assessment and
5 recommendations for On-Site training.”¹²⁶

6 In supplementing Phase Three, ISI explained that Phase Three would be the
7 implementation of the On-Site Plan created as a result of the training and assessment done
8 during Phase Two.¹²⁷ The Phase Three training agenda is similar to, but more detailed, than the
9 Phase Two agenda. Again, ISI would train on the same list of 23 Goals and Objectives.
10 Again, ISI would “Rate Team’s Proficiency” from 1-5 (1 = Beginner, 5 = Expert).¹²⁸ ISI also
11 provided a seven page list of specific tasks, correlated to the list of goals, that the trainees
12 would be required to perform in order to earn their rating. For instance, the table that
13 corresponds with Goal #5 (Patient Positioning and Preparation) requires the nurses and
14 surgeons to “Describe and demonstrate patient position on table matching sample O.R.
15 Procedure.”¹²⁹

16 Unlike the Phase Two agenda, the Phase Three agenda also included a section on
17 “Anesthesia Considerations.”¹³⁰ This portion of the Phase Three curriculum would require
18

19
20 ¹²⁴ PT-10 at 27585.

¹²⁵ PT-10 at 27585.

¹²⁶ PT-10 at 27585.

21 ¹²⁷ PT-10 at 27588 (“This On-Site/Installation Plan is customized for each institution. It is
22 derived from Instructor Assessments of the surgical team at the end of Phase 2 and from a needs
assessment identified by the surgical team and Project Manager.”).

¹²⁸ PT-10 at 27589.

23 ¹²⁹ PT-10 at 27591.

¹³⁰ PT-10 at 27589.

1 participation by the anesthesiologist, nurses, clinical technician, and surgeons.¹³¹ It would
2 require each of these participants to, in various ways: “Explain importance of patient
3 positioning.”¹³² Also unlike Phase Two, Phase Three included a “Dry Run of Procedure with
4 Training Model.”¹³³ The dry run would include a section on the “Interference of ... Patient
5 Anatomy,” which includes demonstration of “Body positioning (patient and table).”¹³⁴

6 Finally, ISI provided further detail on Phase Four, which it described again as “Surgeon
7 Directed Training.”¹³⁵ ISI explained that Phase Four would address “basic and advanced
8 minimally invasive skills applied to the da Vinci™ Surgical System.”¹³⁶ The surgeon, ISI
9 assured, would “identify, perform, and evaluate the specific surgical skills utilized during
10 surgery using the da Vinci™ Surgical System and a training model.”¹³⁷ The surgeon would
11 have “sufficient information to objectively assess and document the results” of this further
12 training due to the “Didactic and practical experiences” conducted during Phase Two.¹³⁸
13 Moreover, ISI promised, the surgeons would complete a “self assessment ... at the completion
14 of Phase Two and/or Phase Three.”¹³⁹

15 ISI even provided the forms that it would use for this self-assessment.¹⁴⁰ These forms
16 required assessment of the “surgical skills used during surgery with the da Vinci Surgical
17 System.” This included assessment of the surgeon’s mastery of the “Principles of
18

19 ¹³¹ PT-10 at 27591.

20 ¹³² PT-10 at 27591.

21 ¹³³ PT-10 at 27593-27594.

22 ¹³⁴ PT-10 at 27593-27594.

23 ¹³⁵ PT-10 at 27597-27960.

¹³⁶ PT-10 at 27597.

¹³⁷ PT-10 at 27597.

¹³⁸ PT-10 at 27597.

¹³⁹ PT-10 at 27597.

¹⁴⁰ PT-10 at 27599-27600.

1 insufflation.” The forms also required assessment of the surgeons’ ability to perform the
2 procedures themselves: i.e., the surgeon would be asked to rate whether they were “able to
3 perform and demonstrate understanding of ... Minimally Invasive Cholecystectomy using the
4 da Vinci™ Surgical System.”¹⁴¹ Likewise, a surgeon receiving training on Nissen
5 Fundoplication would rate, after Phase Two and/or Phase Three, the surgeon’s ability “to
6 perform ... Minimally Invasive Nissen Fundoplication” with the da Vinci Surgical System.¹⁴²

7 In summary, ISI promised the FDA a “comprehensive”¹⁴³ training program marked by
8 “consistent”¹⁴⁴ assessment performed by “experts” using documented and specifically
9 developed “metrics.”¹⁴⁵ Phase One would be distance education followed by a 70-question¹⁴⁶
10 exam, specific “feedback”¹⁴⁷ from an “instructor,”¹⁴⁸ and “remediation.”¹⁴⁹ Phase Two would
11 be a three-day,¹⁵⁰ whole team,¹⁵¹ hands-on¹⁵² training course that would teach the trainees
12 specific patient and table positions for specific procedures,¹⁵³ address insufflator settings,¹⁵⁴
13 and require the surgeons to perform the specific surgical skills¹⁵⁵ for a given surgery. 22 of 23
14 skillsets¹⁵⁶ would be taught, and each of those skillsets would be assessed with a Likert
15

16 ¹⁴¹ PT-10 at 27599.

17 ¹⁴² PT-10 at 27600.

18 ¹⁴³ PT-10 at 27497.

19 ¹⁴⁴ PT-6 at 814.

20 ¹⁴⁵ PT-6 at 814, 815.

21 ¹⁴⁶ PT-6 at 814; PT-10 at 27554-27569.

22 ¹⁴⁷ PT-6 at 815.

23 ¹⁴⁸ PT-6 at 815.

¹⁴⁹ PT-6 at 815.

¹⁵⁰ PT-6 at 815.

¹⁵¹ PT-6 at 815.

¹⁵² PT-6 at 815.

¹⁵³ PT-10 at 27605, 27609.

¹⁵⁴ PT-10 at 27609.

¹⁵⁵ PT-10 at 27612-27613.

¹⁵⁶ PT-10 at 27572 (day one), 27574 (day two), 27580 (day three).

1 rating.¹⁵⁷ This practical experience would also be sufficient¹⁵⁸ to allow for the surgeon to self-
2 assess,¹⁵⁹ at that time, his or her ability to perform the given procedures¹⁶⁰ on humans with the
3 da Vinci robot. The entire surgical team would then work with the expert trainers to create a
4 plan¹⁶¹ for the next phase: implementation. Phase Three implementation would require the
5 console and patient-side surgeons to advance their surgical skills through “intense practice”¹⁶²
6 on “specific procedures”¹⁶³ using “cadaveric models.”¹⁶⁴ Their performance would be
7 compared by ISI against objective metrics and certified for mastery.¹⁶⁵ ISI would also make
8 this assessment data available to the team and the hospital.¹⁶⁶ Phase Three would also require
9 the surgical team to incorporate and educate an anesthesiologist¹⁶⁷ before conducting a “dry
10 run.”¹⁶⁸ Phase Four would ensure the surgeon had “sufficient information to objectively
11 assess”¹⁶⁹ his or her readiness to perform actual, specific procedures: cholecystectomy and
12 Nissen Fundoplication. And ISI promised to “partner”¹⁷⁰ with META to take advantage of
13 META’s “M.Ed. and Ed.D. level personnel”¹⁷¹ as ISI and META further developed and
14 assessed “the curriculum, instructional design, and instructional delivery system for both
15

16 ¹⁵⁷ PT-8 at 2211-2212.

17 ¹⁵⁸ PT-10 at 27597.

18 ¹⁵⁹ PT-10 at 27599-27600.

19 ¹⁶⁰ PT-10 at 27599 (cholecystectomy), 27600 (Nissen fundoplication).

20 ¹⁶¹ PT-10 at 27588.

21 ¹⁶² PT-6 at 815.

22 ¹⁶³ PT-6 at 815.

23 ¹⁶⁴ PT-6 at 815.

¹⁶⁵ PT-6 at 815.

¹⁶⁶ PT-8 at 2214.

¹⁶⁷ PT-10 at 27591.

¹⁶⁸ PT-10 at 27593-27594.

¹⁶⁹ PT-10 at 27597.

¹⁷⁰ PT-6 at 815.

¹⁷¹ PT-6 at 815.

1 training centers and installation sites.”¹⁷² All of this was designed to ensure “demonstrated
2 mastery of competence in applying surgical skills to procedural applications”¹⁷³ *before*
3 surgeons operated unsupervised on live human beings.

4 **C. Having received assurances regarding the proposed training, the FDA
5 reclassifies and clears ISI’s device for marketing of specific procedures.**

6 Shortly after receiving ISI’s “comprehensive Training Package,” the FDA again
7 reclassified ISI’s application, switching back to the less rigorous Premarket Notification
8 process.¹⁷⁴ Importantly, this regulatory change from Premarket Approval to Premarket
9 Notification did not modify the application so far as it concerned ISI’s promises regarding
10 training of surgical teams. ISI thus admits that “the material that had been submitted prior to
11 clearance, even if it was under a PMA designation,” remained “part of the ... file.”¹⁷⁵ As
12 explained by Suzanne Parisian, M.D. – a former FDA Medical Officer and instructor at the
13 FDA’s “staff college” – ISI was *required* to provide no less than the rigorous training program
14 described in its submissions:

15 [I]t’s their responsibility, introducing a new technology, to ensure that the
16 physicians who are using it have adequate training and experience and
17 knowledge before you allow them just to go off with a new device. And they
18 took it upon themselves when they got the 510(k) clearance The company
19 agreed voluntarily that they were going to do this, that it was a commitment.¹⁷⁶

20 In fact, Parisian explained, the only way a product like da Vinci *could* have been cleared via
21 Premarket Notification was with a commitment for “adequate physician training.”¹⁷⁷

22 ¹⁷² PT-6 at 815.

23 ¹⁷³ PT-6 at 815.

¹⁷⁴ PT-135 at 31448.

¹⁷⁵ Exhibit E to Mullenix Declaration (Kreaden Deposition) at 75:25-76:6.

¹⁷⁶ Exhibit F to Mullenix Declaration (Parisian Deposition) at 25:15-25.

¹⁷⁷ Exhibit F to Mullenix Declaration (Parisian Deposition) at 25:25-26:11 (“to make it
equivalent, they have to make sure the physicians are trained to be able to use the product.”).

1 In its Supplemental Brief, ISI asserts that “the FDA did not impose a training
2 requirement on Intuitive” before Intuitive was permitted to market the da Vinci Surgical
3 System.¹⁷⁸ But even ISI’s Chief Medical Officer, Dr. Curet, a CR 30(b)(6) designee,
4 recognized the absurdity of the notion that *no* training was required by the FDA:

5 if the FDA came and asked, we'd be required to prove to them that [ISI's training
6 program] was adequate. So I think it's -- we can't just make a decision because
7 it's easy for us, right? We have to make a decision that would satisfy that the
8 FDA would agree that it was training them -- training the user safely on it.¹⁷⁹

9 Indeed, Dr. Curet has gone further, having published an article stating that ISI’s
10 training program was *mandated* by the FDA.¹⁸⁰

11 Ultimately, on July 11, 2000, the FDA cleared the device for marketing of the two
12 laparoscopic procedures, laparoscopic Cholecystectomy and Nissen Fundoplication, in the
13 United States.¹⁸¹ In an application filed the next month,¹⁸² ISI also sought clearance to
14 advertise its robot for “general non-cardiovascular thoracoscopic procedures such as internal
15 mammary artery mobilization.”¹⁸³ ISI’s application materials for thoracoscopic procedures
16 contained a materially identical training proposal.¹⁸⁴ The FDA cleared that device for

17 ¹⁷⁸ Defendant Intuitive Surgical, Inc.’s Supplemental Brief in Support of Its Motion for
18 Summary Judgment on All Claims and for Partial Summary Judgment on Plaintiffs’ Claim for
19 Punitive Damages, at 2. The parties’ dispute regarding whether the FDA mandated training is
20 not essential to resolution of this motion. The important point about ISI’s extensive
21 representations to the FDA about the type of training it would provide is that they represent
22 ISI’s own description of what it considered an appropriate training program, which contrasts
23 starkly with the training it later provided.

¹⁷⁹ Exhibit G to Mullenix Declaration (Curet Deposition) at 47:13-18.

¹⁸⁰ See PT-68 at ¶ (I)

¹⁸¹ PT-235 (July 11, 2000, clearance letter) at 27472-27474.

¹⁸² See http://www.accessdata.fda.gov/cdrh_docs/pdf/k002489.pdf (accessed Jan. 3, 2013)
(stating application for K002489 was prepared August 8, 2000).

¹⁸³ PT-239 (Clearance Letter for K002489) at 12314-12315.

¹⁸⁴ PT-11 at 10056-10103.

1 marketing, via the Pre-Market Notification process, on March 2, 2001.¹⁸⁵

2 At this point, however, ISI was still not allowed to market its robot in the United States
3 for laparoscopic radical prostatectomy, the procedure Fred Taylor ultimately underwent in
4 September 2008. Rather, as an ISI CR 30(b)(6) designee testified, ISI was required to submit a
5 new pre-market notification to the FDA “every time [ISI] want[ed] to market a procedure in a
6 new surgical specialty for which it doesn't already have clearance.”¹⁸⁶

7 **D. ISI is caught by the FDA improperly marketing its device for prostatectomy.**

8 Although it had not received clearance to market its robot for laparoscopic radical
9 prostatectomy or cardiac procedures, ISI began to do so illegally in early 2001.¹⁸⁷ On February
10 20, 2011,¹⁸⁸ and again on and April 12, 2001,¹⁸⁹ the FDA sent “Warning” letters to ISI about its
11 illegal “off-label” advertising. Specifically, the FDA informed ISI that its “promotion of the
12 device for off-label uses such as prostatectomies and cardiac procedures misbrands and
13 adulterates the da Vinci™ system,” and ordered ISI to take “prompt action to correct these
14 violations.”¹⁹⁰

15 **E. ISI seeks FDA approval for prostatectomy, claiming “substantial equivalence”
16 with its own prior FDA submissions, which included detailed training
programs.**

17 In response to these letters, ISI submitted a Pre-Market Notification application for
18 clearance to advertise for laparoscopic prostatectomy.¹⁹¹ ISI claimed “substantial equivalence”
19

20 ¹⁸⁵ See http://www.accessdata.fda.gov/cdrh_docs/pdf/k002489.pdf (accessed Jan. 3, 2013)
(stating decision of substantial equivalency made March 2, 2001).

21 ¹⁸⁶ Exhibit E to Mullenix Declaration (Kreaden Deposition) at 89:4-6.

22 ¹⁸⁷ PT-136.

23 ¹⁸⁸ PT-136.

¹⁸⁹ PT-27 at 1.

¹⁹⁰ PT-27 at 3.

¹⁹¹ PT-92.

1 with the three indications the FDA had earlier cleared: blunt dissection (K965001),
2 laparoscopic cholecystectomy and Nissen fundoplication (K990144), and internal mammary
3 artery mobilization (K002489).¹⁹² ISI's robotic prostatectomy application did not indicate that
4 it intended to modify the earlier, cleared iterations of its training programs. Rather, it
5 submitted an indication that stated, like the earlier indications, that its robot was "intended to
6 be used by trained physicians in an operating room environment."¹⁹³ ISI's Vice President of
7 Clinical, Regulatory, and Quality Affairs certified to the FDA that "no material fact has been
8 omitted" from the "data and information submitted in this pre-market notification."¹⁹⁴

9 **F. ISI's Gene Nagel drastically reduces the rigor of the training and assessment**
10 **program under the guise of making the program more "efficient."**

11 In November 2000, only four months after receiving its first surgical clearance, ISI
12 hired Gene Nagel to take over (among other things) its surgeon training program. Nagel was
13 not a physician or an educator. His college degree was in marketing and operations
14 management.¹⁹⁵ After college, he had spent thirteen years as a salesman, first on behalf of two
15 wineries, and then at a medical device company.¹⁹⁶ He then spent two years as a manager at the
16 device company, "teaching the salespeople how to sell."¹⁹⁷ When he joined ISI in 2000, he had
17 never had any higher education in the fields of education¹⁹⁸ or "medical related subjects."¹⁹⁹

18 Despite his lack of relevant experience or education, in July 2001, ISI put Nagel in
19

20 ¹⁹² PT-92.

¹⁹³ PT-92.

21 ¹⁹⁴ PT-92 at 3247.

¹⁹⁵ Exhibit B to Mullenix Declaration (Nagel Deposition) at 10:1-11:1; 22:10-18.

22 ¹⁹⁶ Exhibit B to Mullenix Declaration (Nagel Deposition) at 10:1-11:1; 22:10-18.

¹⁹⁷ Exhibit B to Mullenix Declaration (Nagel Deposition) at 11:2-10; 11:15-17.

23 ¹⁹⁸ See Exhibit B to Mullenix Declaration (Nagel Deposition) at 10:5-6.

¹⁹⁹ Exhibit B to Mullenix Declaration (Nagel Deposition) at 19:12-15.

1 charge of its *surgeon* training program.²⁰⁰ Moreover, ISI allowed Nagel to make substantial
2 changes to the surgeon training program without approval from anyone else at ISI.²⁰¹ ISI
3 likewise chose not to partner with META to guide Nagel, despite its promise to the FDA to
4 partner with META “to assess learning needs and develop and refine the curriculum” for the
5 promised surgeon training. Nor did META “assess the pilot program's success and design the
6 curriculum, instructional design, and instructional delivery system for both training centers and
7 installation sites,”²⁰² as ISI had said it would. Rather, ISI's only contract with META
8 concerned the training of ISI's *sales force* in how to best sell ISI's robot.²⁰³

9 Without META's guidance, and under Nagel's unqualified and unchecked direction,
10 ISI drastically reduced the rigor and quality of the training program it had promised the FDA.
11 Nagel testified that he did so because the existing training program was being done
12 “inefficiently in terms of down time.”²⁰⁴ Specifically, the post-Nagel training program was not
13 “comprehensive,” was not marked by “consistent” assessments, was not conducted by
14 “experts,” and was not conducted using developed “metrics.”²⁰⁵ In fact, ISI never required that
15

16 ²⁰⁰ Exhibit B to Mullenix Declaration (Nagel Deposition) at 8:15 (“customer training”); 18:11-
17 23 (took over customer training in approximately July 2001).

18 ²⁰¹ Exhibit B to Mullenix Declaration (Nagel Deposition) at 92:6-10.

19 ²⁰² PT-6 at 815. ISI's failure to work, as promised, with META, is particularly dumbfounding
20 given that Nagel had actually worked with Nagel at the device company he left to join ISI.
21 Exhibit B to Mullenix Declaration (Nagel Deposition) at 117:11-15.

22 ²⁰³ PT-244 (META Letter) at 31583-31584.

23 ²⁰⁴ Exhibit B to Mullenix Declaration (Nagel Deposition) at 81:4; *see generally* Exhibit B to
Mullenix Declaration (Nagel Deposition) at 79:24-85:7. In retrospect, it makes sense that Mr.
Nagel cared so much about making the surgeon training program as short as possible. Damon
Daniels, the ISI salesman who convinced Dr. Bildsten to “commit” to robotic surgery, testified
that the “most common” objection he encountered from surgeons he sought to train was “time.”
Exhibit A to Mullenix Declaration (Daniels Deposition) at 272:11-17. Specifically, surgeons
would say: “I don't have time to take away from my practice, I don't have time to train, I don't
have time to come and spend time with you at the console and practice, time, period.” *Id.*

²⁰⁵ Exhibit H to Mullenix Declaration (Lederer Deposition) at 77:24-78:2.

1 its "expert" trainers have any prior education in medicine or teaching.²⁰⁶

2 With respect to Phase One, ISI did not, under Nagel, provide a 70-question exam
3 followed by specific "feedback" and remediation from an "instructor." Rather, the entirety of
4 Phase One, which was developed and revised in California,²⁰⁷ was simply a video that was less
5 than one hour long and a ten question quiz.²⁰⁸ Moreover, this quiz was impossible to fail
6 because, when a trainee selected an incorrect answer, the online program would simply prompt
7 the trainee to choose a different answer.²⁰⁹ When the trainee finally selected the correct answer,
8 only that correct answer would be recorded in the test taker's final score.²¹⁰ For this reason,
9 *every test-taker receives a perfect score at the end of the exam.*²¹¹ ISI had promised a distance
10 learning program that would "mimic the cognitive activity required during actual performance"
11 and ensure that all trainee surgeons could "[i]dentify and describe System-specific surgical
12 skills." The program Nagel actually delivered for this phase was, in his words, a "very cursory
13 basic overview of the system."²¹²

14
15
16 ²⁰⁶ Exhibit H to Mullenix Declaration (Lederer Deposition) at 16:19-17:3, 51:10-14; Exhibit B
to Mullenix Declaration (Nagel Deposition) at 94:12-15.

17 ²⁰⁷ Exhibit B to Mullenix Declaration (Nagel Deposition) at 65:12-15.

18 ²⁰⁸ PT-5A at 31309-31321; Exhibit B to Mullenix Declaration (Nagel Deposition) at 87:9-11
("I'm the one who -- who made the decision to convert it to an online module with a ten-
question test.").

19 ²⁰⁹ See, PT-5A at 31309 ("Incorrect - Please Try Again"); PT-5 at 40:00-42:43 ("Your Score:
100; Max Score: 100"); Exhibit B to Mullenix Declaration (Nagel Deposition) at 63:5-15,
64:18-21 ("Q. But in this phase, there's no way to fail this test, is there, unless you have a heart
20 attack in the middle or something? A. I don't know.").

21 ²¹⁰ See, PT-5A at 31309 ("Incorrect - Please Try Again"); PT-5 at 40:00-42:43 ("Your Score:
100; Max Score: 100"); Exhibit B to Mullenix Declaration (Nagel Deposition) at 63:5-15,
64:18-21 ("Q. But in this phase, there's no way to fail this test, is there, unless you have a heart
22 attack in the middle or something? A. I don't know.").

23 ²¹¹ See Exhibit B to Mullenix Declaration (Nagel Deposition) at 65:9-10 ("Q. Are you aware of
anybody ever failing this test? A. I'm not.").

²¹² Exhibit B to Mullenix Declaration (Nagel Deposition) at 64:4.

1 Nagel reduced Phase Two from the promised three days down to one.²¹³ He also
2 eliminated participation of the whole team as promised, limiting Phase Two just to the
3 surgeons.²¹⁴ Phase two also did not include the promised training on insufflator settings²¹⁵ or
4 require the surgeons to perform the specific surgical skills for a given surgery.²¹⁶ In fact, at the
5 relevant time, only pigs (not cadavers) were used to train the surgeons trying to learn da Vinci
6 prostatectomy,²¹⁷ and pigs do not even have prostates.²¹⁸ This revised Phase Two was
7 finalized in California.²¹⁹

8 Likewise, and contrary to ISI's promises, no Likert ratings were used in Nagel's Phase
9 Two. In fact, no written forms are used at all.²²⁰ Surgeons were not asked to self-assess, let
10 alone given sufficient information to rate their own performance on a specific procedure.²²¹ In
11 fact, the trainers would often be training two surgeons at the same time, meaning the trainers
12 could watch only *half* of the activities they were supposedly assessing and correcting.²²²

13 At the end of Phase Two, there was no implementation plan created through the joint
14 work of expert trainers and the entire surgical team so as to address specific skills or
15 knowledge deficiencies. (In fact, there were no "expert" trainers.) Thus, that plan did not
16

17 ²¹³ Exhibit B to Mullenix Declaration (Nagel Deposition) at 88:13-89:7, 90:16-90:21; 99:7-8.

18 ²¹⁴ Exhibit B to Mullenix Declaration (Nagel Deposition) at 100:6-100:23.

19 ²¹⁵ PT-10 at 27609; Exhibit B to Mullenix Declaration (Nagel Deposition) at 47:14-15.

20 ²¹⁶ Exhibit H to Mullenix Declaration (Lederer Deposition) at 45:5-10 ("As it relates to urology
is nonspecific."); Exhibit G to Mullenix Declaration (Curet Deposition) at 63:16-19 ("Q. As I
am understanding what you're saying, you're saying ISI does not train on how to do procedures,
including robotic prostatectomy. A. That's correct."); at 76:14-15 ("We aren't in the position to
teach somebody how to do a procedure.").

21 ²¹⁷ Exhibit H to Mullenix Declaration (Lederer Deposition) at 81:18-20.

22 ²¹⁸ PT-243 (Lieberman Article Excerpt) at 18 ("pigs have no fat or prostate gland").

23 ²¹⁹ Exhibit B to Mullenix Declaration (Nagel Deposition) at 67:18-67:6.

²²⁰ Exhibit H to Mullenix Declaration (Lederer Deposition) at 77:24-78:2.

²²¹ Exhibit G to Mullenix Declaration (Curet Deposition) at 100:2-101:1.

²²² Exhibit H to Mullenix Declaration (Lederer Deposition) at 40:1-7.

1 serve as a basis for any Phase Three work. In fact, there was no “standard performance
2 assessment” for *any* phase.²²³ Nagel decided to stop conducting performance assessments and
3 self-assessments in approximately 2002.²²⁴

4 Likewise, Nagel’s Phase Three did not require that surgeons advance their surgical
5 skills through “intense practice” on “specific procedures” using “cadaveric models.”²²⁵ Rather,
6 ISI’s actual Phase Three consisted of a 45 minute “dry run” procedure that took place, without
7 an anesthesiologist, the night before the first surgery on a live human.²²⁶ ISI thus did not
8 compare that performance against objective metrics or certify the surgeons for mastery.²²⁷ Nor
9 could ISI make any such assessment data available to the team or hospital.

10 Phase Four under Nagel was essentially non-existent. ISI does offer to find proctors for
11 trainee surgeons and hospitals, for a fee,²²⁸ but it refused to vouch for the experience of those
12 proctors.²²⁹ As noted for Phase Two, ISI did not ensure the surgeon had “sufficient
13 information to objectively assess” his or her readiness to perform actual, specific procedures.
14 In the absence of those assessments and remediation, Phase Four now consists solely of
15

16 ²²³ Exhibit B to Mullenix Declaration (Nagel Deposition) at 76:24-77:1.

17 ²²⁴ Exhibit B to Mullenix Declaration (Nagel Deposition) at 79:21-23, 81:8-18.

18 ²²⁵ See Exhibit I to Mullenix Declaration (O’Connor Deposition) at 53:23-54:9, 54:11-12.

19 ²²⁶ Exhibit I to Mullenix Declaration (O’Connor Deposition) at 54:11-12 (training between
20 offsite training and first cases consists of 45 minute dry run the night before the first case);
21 Exhibit B to Mullenix Declaration (Nagel Deposition) at 74:4-5.

22 ²²⁷ Exhibit I to Mullenix Declaration (O’Connor Deposition) at 56:2-10 (no written evaluations
23 or testing after Phase Two training).

²²⁸ Exhibit J to Mullenix Declaration (Lohrasbi Deposition) at 54:22-55:1 (ISI told proctors how
much to charge); 59:2-60:4 (ISI charged hospitals \$3,000 for proctoring, \$2,000 of which would
go to the proctor, and \$1,000 of which would go to ISI to reimburse proctor for travel expenses;
ISI would reimburse surgeon only for travel expenses incurred, keeping the remainder).

²²⁹ PT-256 at 25 (“Intuitive does not express or imply that a given proctor on the list satisfies
any credentialing requirement of the User.... all Proctors listed or referred by Intuitive are
independent contractors.”).

1 “advanced training and case observation.”²³⁰ And as later illustrated by Dr. Bildsten’s
2 experience, the “advanced training” that ISI offered to surgeons would *not* be provided the
3 surgeons *before* their first live patient.²³¹ “Advanced training” was offered only to surgeons
4 who had already “done an initial series of cases”²³² on live human beings.

5 A description of the training process to a surgeon by ISI in July 2008 shows the truly
6 abbreviated nature of the surgeon training program implemented under Nagel. That
7 description describes an “online orientation module” that the surgeon could expect to take “1
8 hour,” an “onsite inservice” that the surgeon could expect to take “4 hours,” offsite training on
9 the “porcine model” in California (seven hours), and a “dry run first case” a “day or two prior
10 to first case.”²³³

11 To summarize, even as ISI sought clearance from the FDA to market for prostatectomy,
12 Nagel was reducing ISI’s surgeon training program without review by any medically trained
13 person. ISI did this notwithstanding its claim that its prostatectomy submission was
14 “substantially equivalent” to the two prior premarket notifications, each of which documented
15 a rigorous training program. Moreover, ISI has never notified the FDA of any “changes that
16 were made to that training protocol.”²³⁴ In the words of ISI’s former director of clinical and
17 regulatory affairs: “we did not believe it was necessary to inform FDA with every little change
18 that was made to a training program.”²³⁵

21 ²³⁰ Exhibit B to Mullenix Declaration (Nagel Deposition) at 75:9-13.

22 ²³¹ Exhibit B to Mullenix Declaration (Daniels Deposition) at 250:3-25.

23 ²³² Exhibit B to Mullenix Declaration (Daniels Deposition) at 250:3-25.

²³³ PT-238 (Carson Email of July 1, 2008) at 32425.

²³⁴ Exhibit E to Mullenix Declaration (Kreaden Deposition) at 42:2-4, 66:21-67:5.

²³⁵ Exhibit E to Mullenix Declaration (Kreaden Deposition) at 58:10-12.

1 **G. While the training program that ISI promised the FDA was arguably**
2 **reasonable, the training program ISI has actually implemented is**
3 **unreasonable.**

4 Notably, no urologist has ever failed ISI's "certification" course.²³⁶ Nor is there any
5 indication that any other surgeon has failed any of the other phases of ISI's training
6 program.²³⁷ At trial, the plaintiff will present the testimony of William Helton, M.D. with
7 respect to the reasonableness of the various iterations of ISI's surgeon training programs. Dr.
8 Helton was one of the first general surgeons in America to use ISI's robot, and he also led one
9 of the largest clinical and robotic surgery training programs in America in the early 2000s.²³⁸
10 Dr. Helton has analyzed the material ISI presented to the FDA²³⁹ and the evidence showing the
11 actual training program ISI provided to surgeons when it trained and certified Dr. Bildsten.²⁴⁰

12 Dr. Helton concludes that ISI's initially proposed training program "could have been,"
13 with certain caveats,²⁴¹ "a reasonable introductory training regime for training surgeons on the
14 use of the da Vinci system in surgery."²⁴² However, especially after the Nagel changes, that
15 training program was unreasonably unsafe:

16 7. The actual training program, in use at the time of Dr. Bilstein's training,
17 described by Nagel and Lederer lacks depth and breadth, is incomplete, and is
18 potentially unsafe. There was no logical reason or rationale to scale back the

19

²³⁶ Exhibit H to Mullenix Declaration (Lederer Deposition) at 51:21-24.

20 ²³⁷ Exhibit I to Mullenix Declaration (O'Connor Deposition) at 111:6-14 ("Has any surgeon ever
21 failed the online training? A. Not to my knowledge. Q. To your knowledge, has any surgeon
22 ever failed the on-site training? A. Not to my knowledge. Q. To your knowledge, has any
23 surgeon ever failed the off-site training? A. No.").

²³⁸ Helton Declaration at ¶3.

²³⁹ Helton Declaration at ¶4.

²⁴⁰ Helton Declaration at ¶6.

²⁴¹ Helton Declaration at ¶5. Dr. Helton notes that even ISI's initially promised training regime
would be insufficient if, as in the program ISI actually put in place, (1) the "expert" evaluators
had no medical training and no educational training, and (2) ISI gave inaccurate representations
during training about the learning curve for robotic surgery.

²⁴² Helton Declaration at ¶5.

1 program from the originally proposed training paradigm that was submitted to
2 the FDA and it was inexcusable to do so for the reasons they state. Further, to
3 suggest that any surgeon could be adequately trained to perform any type of
4 major surgery using the da Vinci surgical system after only the level of training
5 proposed is unfounded and unsupported by any data, a leap of faith, potentially
6 unsafe, and irresponsible.

7 8. ... It was *not* reasonable to reduce or scale back that training program as ISI
8 did. Such a reduction in training could put patients at risk; the reasons stated by
9 ISI for reducing that training do not justify that risk. The training program
10 ultimately adopted by ISI and applied to Dr. Bildsten was inadequate and
11 unreasonable to ensure patient safety.^[243]

12 Moreover, Dr. Helton opines that, by the time of the Taylor surgery, ISI should have known
13 (and warned) about the true nature of the learning curve for robotic surgery.²⁴⁴ This
14 knowledge was readily available from a host of published literature, much of which was
15 authored by ISI's "own paid consultants[.]"²⁴⁵ In fact, ISI's most prominent consultant, Dr.
16 Vipul Patel, stated recently (after reviewing literature available in 2008) that the learning curve
17 "to achieve *basic competency* for robotic radical prostatectomy" has been estimated to be
18 between 20 and 25 cases.²⁴⁶ In fact, when training its sales persons, ISI tells those sales
19 persons that a surgeon's 11th through 20th procedures are the "Competence Development"
20 stage.²⁴⁷

21 Dr. Helton, based on his review of the literature available to ISI in September 2008,
22 concludes that ISI acted unethically in failing to fully disclose the nature of the learning curve:

23 ISI had an ethical responsibility to inform Dr. Bildsten that it would likely take
him 20 to 40 procedures before he could safely perform unsupervised da Vinci

243 Helton Declaration at ¶¶7-8.

244 Helton Declaration at ¶¶9-13.

245 Helton Declaration at ¶11.

246 PT-232 (Patel et. al, *Difficult Conditions in Laparoscopic Urologic Surgery* (ISBN 978-1-84882-104-0), Chapter 16: "Difficulties in Robotic Radical Prostatectomy") at 209 (emphasis added).

247 PT-73; Exhibit A to Mullenix Declaration (Daniels Deposition) at 194:8-196:3 (PT-73 accurately reflects the clinical sales process while Damon Daniels was at ISI.)

1 prostatectomy on the average patient, and 50 procedures before he could safely
2 perform unsupervised da Vinci prostatectomy on a patient like Fred Taylor who
3 was not an ideal robotic surgical candidate, especially for a novice surgeon on
4 the robot.²⁴⁸

5 According to Helton, ISI “should also have given warnings of this nature to Harrison Medical
6 Center.”²⁴⁹ As Helton notes, ISI had “numerous”²⁵⁰ opportunities to provide this information
7 to Harrison and Dr. Bildsten, and its decision not to do so was “irresponsible and reckless.”²⁵¹

8 **H. ISI’s business model.**

9 When ISI formed, there was no market for robotic surgery devices. ISI recognized
10 even in the late 1990s that one of its “big issues” was the surgeons’ perception of “how user
11 friendly or patient specific” its robot was.²⁵² It also recognized that it would have to sell
12 initially only to “large, high-volume tertiary care centers who can make the huge capital
13 investment.”²⁵³ It recognized that creating a demand for its “high cost”²⁵⁴ product would
14 depend using patients to create financial pressures on surgeons: “The last thing a surgeon
15 wants is to have a patient walk in and talk about a friend who had a procedure done minimally
16 invasively and have to say, ‘I can’t do that,’ because he knows the patient will look for another
17 doctor.”²⁵⁵ But even in the 1990s, ISI’s goal was to drive the demand for its robot to such an
18 extent that even small hospitals would be forced to purchase the robot: “Ten years from now,
19 will we find these systems in 50-bed hospitals? ... I think it’s a real possibility.”²⁵⁶

20 ISI’s method of achieving that reality is summed up in its sales motto: “Driving the

21 ²⁴⁸ Helton Declaration at ¶15.

22 ²⁴⁹ Helton Declaration at ¶15.

23 ²⁵⁰ Helton Declaration at ¶18.

²⁵¹ Helton Declaration at ¶19.

²⁵² PT-240 (“Has the Real MIS Revolution Finally Arrived”) at 2239.

²⁵³ PT-240 (“Has the Real MIS Revolution Finally Arrived”) at 2243.

²⁵⁴ PT-240 (“Has the Real MIS Revolution Finally Arrived”) at 2238.

²⁵⁵ PT-240 (“Has the Real MIS Revolution Finally Arrived”).

²⁵⁶ PT-240 (“Has the Real MIS Revolution Finally Arrived”) at 2243.

1 Curve.”²⁵⁷ The “curve” in question is the “adoption curve” for robotic surgery,²⁵⁸ i.e., the
2 extent to which surgeons are performing given surgeries with the da Vinci robot as opposed to
3 with open procedures or even non-robotic laparoscopy. ISI’s express goal was to make the use
4 of its robot the “Standard of Care”²⁵⁹ for surgeons. And its sales documents from 2007 show
5 that ISI was, at that time, intensely focused on “da Vinci Prostatectomy” (“dVP”): “2007
6 Marketing Strategy: dVP in every account!”²⁶⁰ ... Drive incremental dVP growth at all
7 hospitals!”²⁶¹ Pushing “dVP” in 2007 was labeled, to ISI’s sales trainees, as ISI’s “**Highest**
8 **Priority**”.²⁶²

9 ISI’s efforts were remarkably successful. By the end of 2007, according to ISI, more
10 than 60 percent of all prostatectomies nationally were being performed with the da Vinci
11 robot.²⁶³ Locally, by 2008, ISI had already sold (multimillion dollar) robots to eight Seattle-
12 and Tacoma-area hospitals.²⁶⁴ Swedish Medical Center had already purchased a *second*
13 robot.²⁶⁵

14 By July 2008, ISI’s procedure goals for dVP had grown even more ambitious. ISI’s
15 July 2008 Sales and Marketing Plan demanded that that its sales force “[d]rive dVP to
16 standard-of-care in every market by achieving a minimum of 20 dVPs in every [hospital], in
17 every quarter.”²⁶⁶ Higher level salespersons were responsible for a “minimum” of six
18

19 ²⁵⁷ See, e.g., PT-29 at 414.

20 ²⁵⁸ Exhibit B to Mullenix Declaration (Nagel Deposition) at 188:22-23.

21 ²⁵⁹ PT-29 at 409.

22 ²⁶⁰ By “account,” ISI was referring to hospitals that had purchased robots.

23 ²⁶¹ PT-29 at 412.

²⁶² PT-29 at 404.

²⁶³ PT-1 at 1016.

²⁶⁴ PT-1 at 1019.

²⁶⁵ PT-1 at 1019.

²⁶⁶ PT-149 at 31894.

1 “greenfield” sales in 2008.²⁶⁷ “Greenfields” were hospitals buying a robot for the first time,
2 with no prior surgical robotics programs. Thus, those salespersons were each required to sell
3 robots to six *new* hospitals in a single year. Because major hospitals had each already
4 purchased systems by that time, ISI’s sales force understood that *smaller* hospitals must be
5 their focus. In the words of one of ISI’s local salesmen: “Hospitals like Harrison are our
6 future.”²⁶⁸

7 Other high level ISI sales persons were required to make at least three “second system”
8 sales in 2008.²⁶⁹ To do so, those sales persons were required to “Create demand for additional
9 da Vinci System acquisitions” by driving “procedure growth”²⁷⁰ at hospitals that had already
10 bought robots. By driving procedure growth, i.e., increasing the number of procedures at a
11 given hospital that were performed with the robot, ISI could create “capacity and scheduling
12 constraints” that would lead to “additional system sales.”²⁷¹

13 To drive procedure growth, ISI trained a large section of its sales force in “clinical”
14 sales. These “Clinical Sales Representatives” (“CSRs”) were judged and paid not on selling
15 robots, but rather on the extent to which they were able to convince surgeons to *use* robots: i.e.,
16 to “maximize the utilization of installed da Vinci Surgical Systems.”²⁷² ISI provided “case
17 volume goals” to these CSRs, and it considered those goals “the only measure of success.”²⁷³

18 For this reason, ISI actually paid its CSRs through a quota system based on *how many*
19 *procedures were performed in the hospitals to which the CSR’s were assigned.* For instance, in

20 ²⁶⁷ PT-149 at 31894.

21 ²⁶⁸ PT-188.

22 ²⁶⁹ PT-227 (Drive the Curves 2008) at 31895.

23 ²⁷⁰ PT-227 (Drive the Curves 2008) at 31895.

²⁷¹ PT-227 (Drive the Curves 2008) at 31895.

²⁷² PT-80; Exhibit A to Mullenix Declaration (Daniels Deposition) at 189:19-90:10.

²⁷³ PT-192.

1 2008, the CSR assigned to Harrison Medical Center (Damon Daniels) was promised a \$65,000
2 base salary.²⁷⁴ However, if the surgeons to whom Daniels was assigned performed the
3 required number (“quota”) of surgeries, Daniels would receive \$120,000 *more* per year plus a
4 likely \$15,420 in commissions for additional instrument sales.²⁷⁵ If Daniels’s surgeons
5 performed more than 10 percent above quota, he received an automatic *additional* 15 percent
6 bonus, making his total bonus \$138,000. Consequences for failure were similarly stark: failing
7 to hit at least 90 percent of the quota would mean a 75 percent *reduction* in procedure-based
8 bonuses for Daniels in 2008.²⁷⁶ As Daniels’s manager (Sean O’Connor) warned him one
9 month before the Taylor surgery: “Missing quota by one case is a significant financial hit.”²⁷⁷

10 To enable its CSRs to convince surgeons to use its robot, ISI made a massive
11 investment in *clinical* training of its sales staff. In contrast with its one-day surgeon training
12 program, ISI’s sales training was *nine* weeks long.²⁷⁸ It consisted of a three-week distance
13 education course, four²⁷⁹ to six²⁸⁰ weeks of intensive residential “Clinical and Sales Training”
14 (“CAST”) and then two more weeks of “field training” with an experienced CSR known as a
15 “Field Trainer,”²⁸¹ followed by another week of “advanced CAST” in California.²⁸² One of the
16 purposes of this training was to develop the CSRs’ “Equal Clinical Stature skillsets,”²⁸³ *i.e.*, to
17 develop the CSRs’ understanding of anatomy and medical terminology so that they have

18 _____
19 ²⁷⁴ PT-172 at 34222.

20 ²⁷⁵ PT-172 at 34222.

21 ²⁷⁶ PT-172 at 34222.

22 ²⁷⁷ PT-197.

23 ²⁷⁸ Exhibit A to Mullenix Declaration (Daniels Deposition) at 168:14-19; *see also* Exhibit B to
Mullenix Declaration (Nagel Deposition) at 50:16-17.

²⁷⁹ Exhibit A to Mullenix Declaration (Daniels Deposition) at 168:14-16.

²⁸⁰ Exhibit K to Mullenix Declaration (Carson Deposition) at 47:17-22.

²⁸¹ Exhibit A to Mullenix Declaration (Daniels Deposition) at 168:14-19.

²⁸² Exhibit B to Mullenix Declaration (Nagel Deposition) at 159:20-22.

²⁸³ PT-70.

1 credibility when “talking about clinical benefits” with surgeons.²⁸⁴ All CAST training was
2 held at ISI headquarters in California.²⁸⁵

3 Once the CSRs emerged from CAST and field training, ISI provided each CSR with a
4 “Clinical Sales Manager.” The job of the CSM was to constantly monitor the CSR’s progress.
5 The CSM would hold weekly meetings with a small group of CSRs to motivate the CSRs and
6 refine their sales techniques. These CSMs even required the CSRs to read new sales books
7 each quarter.²⁸⁶ The book for the fiscal quarter in which Fred Taylor’s surgery occurred was
8 called “Hardball Selling.”²⁸⁷

9 In addition to this constant monitoring, all of ISI’s sales force would meet annually for
10 a week at a time at ISI’s “World Wide Sales Meetings.” At these meetings, ISI would continue
11 the training by, for instance, teaching the CSRs how to persuade urologists that da Vinci
12 Prostatectomy was a better option than brachytherapy, or external beam radiation therapy.²⁸⁸
13 They would also further develop the CSRs’ “equal clinical stature” skillsets by providing
14 scripts to be memorized in how to “handle objections” from surgeons about the limitations or
15 difficulty of using of ISI’s robot.²⁸⁹

16 As a result of these trainings, ISI held high expectations for its CSRs. ISI’s CSRs were
17 expected to “[b]ecome a clinical expert across all primary OR procedures” in which the robot
18 could be used.²⁹⁰ One of a CSR’s “core activities” was to “Develop surgeon competence.”²⁹¹

19
20 ²⁸⁴ Exhibit P to Mullenix Declaration (Thompson Deposition) at 24:22-25:8.

21 ²⁸⁵ Exhibit K to Mullenix Declaration (Carson Deposition) at 48:14-22; Exhibit B to Mullenix
22 Declaration (Nagel Deposition) at 136:7-9.

23 ²⁸⁶ PT-199; Exhibit I to Mullenix Declaration (O’Connor Deposition) at 189:1-8.

²⁸⁷ PT-199; Exhibit I to Mullenix Declaration (O’Connor Deposition) at 189:1-8.

²⁸⁸ PT-31.

²⁸⁹ PT-102.

²⁹⁰ PT-80; Exhibit A to Mullenix Declaration (Daniels Deposition) at 189:19-190:10.

1 ISI expected CSRs to position themselves “as a partner in the development of surgical teams,”
2 and even “[d]evelop a clinical plan for each surgical team to insure they are capable of using
3 the system independently within reasonable time frame.”²⁹² And ISI expected CSRs to
4 “[d]rive utilization of the da Vinci” by “partnering with surgical teams to *review and select*
5 *appropriate cases* and insure consistent usage of the da Vinci.”²⁹³

6 Importantly, other than the training they received at ISI, these CSRs had no medical or
7 educational training. Damon Daniels, the CSR who worked with Dr. Bildsten, for example,
8 had a 1995 business degree.²⁹⁴ Nor has any other member of ISI’s sales force yet deposed in
9 this case had any prior medical or educational training.²⁹⁵ Nonetheless, ISI expected these
10 CSRs to be able to successfully challenge reluctant surgeons to convert previously scheduled
11 open surgeries into robotic surgeries.²⁹⁶ As one ISI Clinical Sales Director put it to a group of
12 CSRs over whom he had direct authority:

13 We've all invested a lot of energy into developing our Equal Clinical Stature skill
14 sets. It is now a matter of putting all of that practice to action. Be proactive in
15 finding cases to convert. Be prepared to challenge each trained surgeon every
16 time you see a lap or open case. Be unsatisfied with the thought of ending a day
17 without a converted case.^[297]

18 “Converting,” in this context, means finding a scheduled operation that a surgeon has decided
19 to do without a robot, and convincing him against his initial judgment, to operate with the da
20 Vinci.

21 ²⁹¹ Exhibit A to Mullenix Declaration (Daniels Deposition) at 193:21-194:4; PT-57.
22 ²⁹² PT-80; Exhibit A to Mullenix Declaration (Daniels Deposition) at 189:19-190:10.
23 ²⁹³ PT-80 (emphasis added); Exhibit A to Mullenix Declaration (Daniels Deposition) at 189:19-
190:10.
²⁹⁴ PT-33.
²⁹⁵ Paragraph 6 of Mullenix Declaration.
²⁹⁶ See, e.g., PT-70.
²⁹⁷ PT-70; *see also* Exhibit L to Mullenix Declaration (Ziegler Deposition) at 13:4-7 (ISI sales policies do not differ in significant ways between different geographical areas).

1 ISI knew that its sales force would not be effective at challenging the clinical
2 judgments of trained surgeons unless the sales persons believed fully in the value of da Vinci
3 surgery. Accordingly, ISI chose not to teach its sales persons that new robotic surgeons might
4 be dangerous to their patients,²⁹⁸ that new robotic surgeons would have higher complication
5 rates,²⁹⁹ or “anything” that would make a CSR “question the value of da Vinci® surgery.”³⁰⁰

6 Instead, ISI actually minimized the danger that new robotic surgeons posed to patients
7 by teaching its CSRs to pressure hospitals to adopt only minimal credentialing and privileging
8 requirements. The primary credentialing protections that hospitals would adopt for patients of
9 new robotic surgeons were (1) completion of ISI’s training program and (2) “proctoring,” i.e.,
10 the personal supervision of a new robotic surgeon’s procedures by an experienced robotic
11 surgeon for some number of cases. Proctoring, stood in the way of ISI’s goal of “driving” the
12 adoption curve, however, because the higher a hospital’s proctored procedure requirement, the
13 less likely a surgeon would be to incorporate the robot into the practice, for two main reasons.
14 First, the proctor surgeon would have to be paid \$2,000-\$3,000 per procedure by either the
15 hospital or the surgeon, which made it more difficult for the CSR to convince new surgeons to
16 perform procedures with the robot.³⁰¹ Second, the proctor surgeon’s availability would limit
17 the trainee surgeon’s ability to book cases, meaning the surgeons would be unable to perform
18 as many procedures as they could otherwise perform.³⁰²

19 ISI was able to combat this proctoring problem by having its sales persons closely

20 ²⁹⁸ Exhibit A to Mullenix Declaration (Daniels Deposition) at 169:16-19.

21 ²⁹⁹ Exhibit A to Mullenix Declaration (Daniels Deposition) at 169:20-24.

22 ³⁰⁰ Exhibit A to Mullenix Declaration (Daniels Deposition) at 169:25-170:5.

23 ³⁰¹ Exhibit A to Mullenix Declaration (Daniels Deposition) at 245:4-246:2.

³⁰² See PT-215 (“I have challenged him to get at least one more case on by the end of the month so that he can have the freedom to book his cases at his convenience, without having to worry about the logistics of a proctor.”).

1 associate themselves with the robotics steering and credentialing committees at the
2 “Greenfield” hospitals.³⁰³ These Greenfield hospitals relied so heavily on ISI’s expertise that
3 ISI would sometimes even set the agendas for the steering committee meetings.³⁰⁴
4 Credentialing boards in such situations would look to ISI for guidance in adopting
5 credentialing criteria.³⁰⁵ ISI’s non-medically trained sales persons would then respond by
6 either (1) providing credentialing examples from other hospitals that had adopted only minimal
7 requirements (and not providing those examples of hospitals that had adopted difficult
8 requirements), or (2) outright telling the hospitals that their proposed credentialing
9 requirements were too high, even if that proposed requirement was as low as five proctored
10 surgeries.³⁰⁶

11 ISI’s efforts to “drive the curve” have worked. According to its website, 2,462 da Vinci
12 systems have been installed in over 1,936 hospitals worldwide.³⁰⁷ As explained below, the CSR
13 whose conduct is primarily at issue in this case (Damon Daniels), also achieved great success as a
14 result of ISI’s training. In fact, he was the top CSR in the entire world for the year of the Taylor
15 surgery.³⁰⁸ For context, ISI had 700 sales employees at the end of 2010.³⁰⁹ Daniels was even
16 promoted by ISI in 2009.³¹⁰

18 ³⁰³ “Greenfield” was the term ISI uses to describe hospitals without a da Vinci.

19 ³⁰⁴ PT-192.

20 ³⁰⁵ See Exhibit A to Mullenix Declaration (Daniels Deposition) at 202:15-23; 203:23-204:3;
21 205:3-9; 225:3-7; 225:13-16; Exhibit I to Mullenix Declaration (O’Connor Deposition) at
22 140:18-141:5; 141:13-23; Exhibit M to Mullenix Declaration (Gillam Deposition) at 14:1-19;
23 PT-137; Exhibit N to Mullenix Declaration (Sanders Deposition) at 26:20-25.

24 ³⁰⁶ See PT-137

25 ³⁰⁷ http://www.intuitivesurgical.com/products/products_faq.html#19 (available: online; accessed
26 Jan. 17, 2013).

27 ³⁰⁸ Exhibit A to Mullenix Declaration (Daniels Deposition) at 66:18-20; PT-33.

28 ³⁰⁹ PT-257 (2011 ISRG Annual Report) at 10.

29 ³¹⁰ PT-33.

1 **I. The ISI “Recommendations,” “Clinical Pathway,” and “Partnership.”**

2 Although ISI denies in this litigation that it is willing or able to teach surgeons how to
3 perform robotic procedures,³¹¹ it admits that it provides each urologist it trains,³¹² before the
4 Sunnyvale training, with a document entitled: “The Clinical Pathway and Training Protocol for
5 da Vinci Prostatectomy.”³¹³ When training its salespeople, ISI defines this Clinical Pathway
6 document as a “[p]rescribed, stepwise approach for surgeons and OR staff to develop
7 knowledge and skills using the da Vinci Surgical System *in clinical applications*.”³¹⁴ In fact,
8 the CSRs understood that an ISI certification meant the surgeons had successfully completed
9 “the protocol for their specialty” and were able to apply surgical skills “to procedural
10 applications.”³¹⁵ CSRs were explicitly told: “All necessary training for surgeons and nurses is
11 built into the clinical plan.”³¹⁶

12 These representations about the comprehensive nature of ISI’s training program were
13 consistent with those ISI made to hospitals and the medical community at large. For instance,
14 in 2007, ISI’s California-based³¹⁷ marketing department authored a chapter in a “Robotic
15 Urology”³¹⁸ textbook. The chapter stated without qualification that: “Intuitive Surgical’s
16 ***Comprehensive*** Clinical Training Continuum helps *ensure* optimal safety, efficacy, and
17

18 ³¹¹ Exhibit G to Mullenix Declaration (Curet Deposition) at 76:14-15 (“We aren’t in the position
19 to teach somebody how to do a procedure.”)

20 ³¹² Exhibit A to Mullenix Declaration (Daniels Deposition) at 231:23-25 (“Q. Were there ever
21 times when you didn’t go over the clinical pathway with a surgeon? A. No.”).

22 ³¹³ PT-42, Ex. A.

23 ³¹⁴ PT 212 (emphasis added); Exhibit A to Mullenix Declaration (Daniels Deposition) at
24 258:10-22; 211:17-18 (“I told [surgeons] ... here’s our clinical pathway document, you know,
25 you should abide by this”).

26 ³¹⁵ Exhibit A to Mullenix Declaration (Daniels Deposition) at 266:1-8.

27 ³¹⁶ PT-30 at 10878; Exhibit B to Mullenix Declaration (Nagel Deposition) at 59:10-11.

28 ³¹⁷ PT-104 at XXII.

29 ³¹⁸ PT-104.

1 utilization of each Da Vinci system.”³¹⁹ ISI also provided Greenfield hospitals (including
2 Harrison)³²⁰ with a document, on ISI letterhead, that is entitled: “Recommendations for
3 Building a da Vinci Robotic Surgery Program.”³²¹ That document recommends as a
4 “fundamental best practice”³²² that surgeons “Follow the Prescribed Clinical Pathway,”³²³
5 which “Your Intuitive Surgical Clinical Sales Manager (CSM) will establish ... with you.”³²⁴
6 When presenting that document to Harrison during early sales meetings, ISI likewise told
7 Harrison it was a “Best Practice” for “surgeons and staff” to “Follow Intuitive’s prescribed
8 training pathway.”³²⁵ Similarly, ISI told Harrison that “[p]artnership with Intuitive Surgical”
9 was a “Best Practice” because ISI had “experience from 600 other launches”.³²⁶ As part of that
10 process, ISI even promised the trainee surgeons and new hospitals: “Your Clinical Sales
11 Representative will help measure your progress against state-of-the-art technique.”³²⁷ (ISI
12 makes this representation to hospitals like Harrison even though its Chief Medical Officer
13 claims ISI “is not in a position to measure a surgeon’s performance against state of the art
14 technique.”)³²⁸ This is all part of ISI’s overarching assurance that it will play an active role in
15 ensuring the success of the program: “The success of your implementation is a direct reflection
16 of our effectiveness and our support.”³²⁹ These educational and marketing materials all

18 ³¹⁹ PT-104 at 259 (emphasis added).

19 ³²⁰ Exhibit K to Mullenix Declaration (Carson Deposition) at 32:19-33:2.

20 ³²¹ PT-72.

21 ³²² PT-72 at 1.

22 ³²³ PT-72 at 1.

23 ³²⁴ PT-72 at 6.

³²⁵ PT-1 at 1026.

³²⁶ PT-1 at 1026.

³²⁷ PT-72 at 6.

³²⁸ Exhibit G to Mullenix Declaration (Curet Deposition) at 99:23-100:1.

³²⁹ PT-72 at 8.

1 originate from California.³³⁰

2 ISI's "Recommendations for Building a da Vinci Robotic Surgery Program" document is
3 also important in that it runs wholly counter to ISI's central theme in its summary judgment brief:
4 that ISI training pertains to nothing but "the use of the da Vinci System" and specifically *does not*
5 pertain to "a specific medical procedure."³³¹ In fact, ISI has a da Vinci Prostatectomy Procedure
6 Guide that takes a urologist through every step of a robotic prostatectomy.³³² In the
7 "Recommendations for Building a da Vinci Robotic Surgery Program," surgeons are instructed
8 that as part of their training, they are to "[l]earn the procedure guide."³³³ This is recommended by
9 ISI as a "fundamental best practice."³³⁴

10 Likewise, the Clinical Pathway document also states that it is a "Training Protocol" for
11 a specific kind of *procedure*: "da Vinci Prostatectomy." The Clinical Pathway states that it has
12 been put "in place" to "ensure success in becoming a proficient robotic surgeon."³³⁵ And the
13 Clinical Pathway also states that it represents the "best practices around the country[.]"³³⁶

14 Among these purported "best practices" was a requirement that "2 cases must be
15 booked" before offsite training would even be allowed by ISI.³³⁷ In other words, ISI required
16 the surgeons to book patients for robotic surgery *before those surgeons had received any*
17 *robotic training*. ISI even threatened: "Training will be cancelled if cases are not booked."³³⁸

18 With respect to proctoring, ISI recommended as a "best practice" that each trainee surgeon

19 _____
20 ³³⁰ Exhibit B to Mullenix Declaration (Nagel Deposition) at 24:18-24. PT-104 at XXII.

³³¹ See, e.g., ISI MSJ at 12.

³³² PT-13.

³³³ PT-73 at 6.

³³⁴ PT-73 at 1.

³³⁵ PT-42, Ex. A.

³³⁶ PT-42, Ex. A.

³³⁷ PT-42, Ex. A at HEDGES 0041.

³³⁸ PT-42, Ex. A at HEDGES 0041.

1 have only two proctored cases before beginning to work unsupervised.

2 Perhaps the most striking aspect of Pathway, however, is its intense focus on
3 commitment to robotic surgery. The Pathway states in its first paragraph that becoming “a
4 skilled robotic surgeon” takes “a high level of commitment early in the case series[.]”³³⁹ ISI’s
5 sales persons even treat these Clinical Pathway documents as “contracts.”³⁴⁰ The CSRs ask the
6 surgeons to *sign* the “contracts.”³⁴¹ They do so for the express purpose of “gain[ing]
7 commitment” from the trainee surgeon.³⁴² The CSRs then keep and maintain copies of those
8 signed contracts,³⁴³ telling the doctors that the CSRs will “help them maintain their
9 commitment to robotic surgery” and “hold them accountable.”³⁴⁴

10 In gaining this commitment, the CSRs would position themselves so that the surgeons
11 viewed them “as a partner.”³⁴⁵ ISI even taught CSRs to portray themselves as “a strong
12 partner” with the hospital.³⁴⁶ As ISI put it, in the Recommendations document given to
13 Greenfields: “Behind every successful robotic surgery program is not only a great deal of
14 effort, but also a strong partnership with Intuitive Surgical. . . . With this in mind, we would
15 like to be closely involved in the development and execution of your program.”³⁴⁷

16 Despite their portrayal as “partners,” the CSRs were by no means fully forthcoming
17

18 ³³⁹ PT-42, Ex. A.

19 ³⁴⁰ Exhibit A to Mullenix Declaration (Daniels Deposition) at 230:1-6, 231:9-10.

20 ³⁴¹ Exhibit A to Mullenix Declaration (Daniels Deposition) at 259:13-16.

21 ³⁴² Exhibit A to Mullenix Declaration (Daniels Deposition) at 259:17-23.

22 ³⁴³ Exhibit A to Mullenix Declaration (Daniels Deposition) at 231:9-11.

23 ³⁴⁴ Exhibit A to Mullenix Declaration (Daniels Deposition) at 212:1-6.

³⁴⁵ Exhibit A to Mullenix Declaration (Daniels Deposition) at 212:14.

³⁴⁶ Exhibit A to Mullenix Declaration (Daniels Deposition) at 197:5-17.

³⁴⁷ PT-72 at 1; see also PT-53 at 4143 (“Behind every successful da Vinci Surgery program is a strong partnership with Intuitive Surgical. Through the implementation of more than 930 da Vinci Surgery programs around the world, Intuitive Surgical has acquired the expertise and experience to facilitate development of a successful da Vinci program.”).

1 with the partner surgeons or hospitals. For instance, the CSRs would “never” tell the surgeons
2 that the CSRs had a financial incentive to make sure that the surgeons actually performed
3 procedures on humans with the robot.³⁴⁸ Likewise, the CSRs would not tell the hospital
4 steering committees that the CSRs “would be compensated based on the number of procedures
5 done with the robot.”³⁴⁹ Rather, ISI’s sales force learn to portray itself as entirely altruistic:
6 “Everything we do is for the benefit of the patient.”³⁵⁰

7 **J. ISI approaches Harrison in April 2008.**

8 In April 2008,³⁵¹ Dave Carson, an ISI “Area Sales Manager,” began the process of
9 convincing Harrison Medical Center to spend nearly \$1.8 million on a surgical robot that no
10 Harrison surgeon knew how to use. Intuitive had trained Carson that, to make such a sale, it
11 was important to “[f]oster a competitive landscape between hospitals and surgeons.”³⁵²

12 In doing so, Carson first recognized that, at that time, Harrison was “being challenged”
13 by a new Gig Harbor hospital scheduled to open in 2009: Saint Anthony’s.³⁵³ Carson knew
14 that the urologists who were performing surgeries at Harrison were “in discussions with
15 Franciscans to move their practice to Gig Harbor.”³⁵⁴ Thus, to increase the pressure on Harrison
16 to buy a robot, Carson began meeting with several Kitsap Peninsula surgeons, including the
17 surgeons of Kitsap Colorectal, Kitsap Obstetrics and Gynecology, and Dr. Bildsten’s clinic:
18 Kitsap Urology.³⁵⁵ He convinced each of these groups to send letters to the executives at
19

20 ³⁴⁸ Exhibit A to Mullenix Declaration (Daniels Deposition) at 274:18-21.

21 ³⁴⁹ Exhibit A to Mullenix Declaration (Daniels Deposition) at 275:10-13.

22 ³⁵⁰ Exhibit L to Mullenix Declaration (Ziegler Deposition) at 42:25-43:1.

23 ³⁵¹ PT-105.

³⁵² PT-254 at 4100.

³⁵³ PT-105.

³⁵⁴ PT-105.

³⁵⁵ See PT-251; Exhibit K to Mullenix Declaration (Carson Deposition) at 141:6-25.

1 Harrison, urging them to purchase a robot.³⁵⁶

2 At the same time, Carson began to exert pressure on Harrison by informing them that
3 another of Harrison's "competitors," St. Joseph's Hospital in Tacoma (CHI), was in the
4 process of buying its second robot.³⁵⁷ Carson informed Harrison that "historically," CHI had
5 requested "market protection" from ISI, i.e., that CHI would negotiate its purchase so that ISI
6 would not sell robots to CHI's competitors in the same geographical area.³⁵⁸ In other words, to
7 create urgency for Harrison, ISI threatened to make an agreement with Harrison's competitor
8 that would cause Harrison to lose patients. Internal ISI emails show that Carson and his
9 Clinical Sales Manager worked together to convince Harrison that "market protection" was a
10 real, potentially devastating, threat.³⁵⁹

11 While he applied all of this pressure, Carson also made numerous representations about
12 the effectiveness of ISI's training program.³⁶⁰

13 Intuitive Surgical would like to be an integral part of your *da Vinci* Surgery
14 program. We can:

- 15 Take the lead in coordinating *da Vinci* System installation, on-site training,
staff in-servicing and surgeon training
- 16 Be part of the robotics steering committee if the hospital decides it is
necessary

17 * * *

- 18 Work with surgeons to develop and execute their clinical paths

19 * * *

20 ³⁵⁶ See PT-251.

21 ³⁵⁷ Exhibit K to Mullenix Declaration (Carson Deposition) at 68:16-69:1.

22 ³⁵⁸ Exhibit K to Mullenix Declaration (Carson Deposition) at 73:1-7.

23 ³⁵⁹ Exhibit I to Mullenix Declaration (O'Connor Deposition) at 166:18-167:2; *see also* PT-258
(June 6, 2008, email) at 32713 ("How did you want me to fwd this [market protection request]
on to you?"); PT-259 to Mullenix Declaration (June 9, 2008, email) at 32287 ("Please do not
commit to any market protection requests from St. Joe's until I get back to you on Wednesday.
I will bring this up to them in person tomorrow night.").

³⁶⁰ PT-108 at 30611.

- Actively support cases in the OR; ...
- Work with entire team to develop technical competency [³⁶¹]

With respect to training, Carson told Harrison's purchasing staff that ISI's training programs were "designed to provide surgeons with the knowledge and skills necessary to utilize the da Vinci S Surgical System *for its intended use in a variety of endoscopic surgical procedures.*"³⁶² He told Harrison the training would be performed by "Experienced faculty."³⁶³ And he promised ISI would make "Surgeon led proctoring" available for \$3,000.³⁶⁴ And to help the Harrison executives justify the expense of the purchase, Carson even provided them with a draft "Business Plan for the da Vinci Robotic Surgery System At Harrison Medical Center."³⁶⁵

K. ISI illegally informs Harrison that its device has been "approved" by the FDA.

ISI's sales tactics included repeatedly suggesting to Harrison that the FDA had "approved" its device for certain surgical procedures. As even ISI's retained FDA expert (Phillip Phillips) will explain at trial, FDA regulations bar device companies from doing anything to suggest that the FDA has given official approval of a device unless the manufacturer has successfully put the device through the rigorous Premarket Approval process.³⁶⁶ Nevertheless, ISI directed communications squarely at Harrison that stated that its system had been "approved" by the FDA. For instance, the "Business Plan" that ISI provided to Harrison to support the purchase stated – misleadingly – that da Vinci gynecologic surgery

³⁶¹ PT-72 at 8.

³⁶² PT-108 at 30611 (emphasis added).

³⁶³ PT-108 at 30611.

³⁶⁴ PT-108 at 30611.

³⁶⁵ PT-115.

³⁶⁶ Exhibit O to Mullenix Declaration (Phillips Deposition) at 65:10-20 ("A. ... there is a regulation that prohibits suggesting that anything cleared through 510(k) is an approval by FDA. Q. And that regulation goes on to say that suggesting that is considered misleading and misbranding; correct? A. That's correct. Q. And in fact, when a device is cleared under 510(k), it does not indicate approval of the device by FDA? A. That's correct.").

1 was “FDA-approved” in May 2005.³⁶⁷ Likewise, another sales communication with Harrison
2 states ISI’s robot “has been used in over 100 different types of surgical procedures.”³⁶⁸ After
3 listing a “sampling” of some 44 different procedures, ISI then states to Harrison: “*Certain*
4 *clinical applications have not yet been approved in the US.*”³⁶⁹ In reality, no procedure has ever
5 been “approved” in the US.³⁷⁰

6 These communications to Harrison were not isolated incidents. In fact, one of ISI’s
7 own paid consultants stated in a published article that the FDA had approved some forms of da
8 Vinci surgery, and ISI would regularly provide that article to surgeons and hospitals.³⁷¹ ISI’s
9 press release templates all stated, incorrectly, that the robot received “FDA approval ... in
10 2001.”³⁷² Even ISI’s chapter in the textbook, *Robotic Urology* stated that ISI had received
11 “U.S. Food and Drug Administration approval in 2005.”³⁷³

12 **L. The Sale and Implementation at Harrison.**

13 Not surprisingly, Harrison ultimately agreed to buy a robot. The sale was finalized on
14 June 20, 2008.³⁷⁴ For the robot, and a five year service plan, Harrison paid \$1,754,500. With
15 Harrison’s instrumentation order, the total purchase price was \$1,870,167.50.³⁷⁵ Although
16

17 ³⁶⁷ PT-115 at 30651.

³⁶⁸ PT-108 at 30610.

18 ³⁶⁹ PT-108 at 30610 (emphasis added).

³⁷⁰ See Parisian Report at 8 (citing 21 C.F.R. § 807.97 (1996)).

19 ³⁷¹ See, e.g., PT-122 at 30 (“The da Vinci robot ... remains the only Food and Drug
20 Administration (FDA)- approved master–slave surgical system still in existence able to provide
21 the benefits necessary for the facile performance of robotic surgery.”); *id.* at 29 (stating Dr.
Patel a “paid consultant” of ISI); Exhibit __ to Mullenix Declaration (Thompson Deposition) at
57:9-19 (stating that Thompson regularly provides PT-122 to customers).

22 ³⁷² PT-229 (Press Release) at 31870; see also PT-260 (ISRG Q2 2012 Earnings Call Transcript)
at 11 (“we are FDA approved in the US for chole”).

³⁷³ PT-104.

23 ³⁷⁴ PT-110 at 30631.

³⁷⁵ PT-120.

1 training of surgeons could be purchased separately from the robot, ISI included free training
2 for six surgeons:

3 Intuitive shall provide training in the use of the System to Purchaser's surgical
4 personnel. As of the Effective Date of this Agreement the price for such
5 Training shall be three thousand dollars (\$3000) per surgeon or physician's
6 assistant. Notwithstanding the above Intuitive agrees to provide training to six
7 (6) surgeons as set forth above, at no charge, provided such training is completed
8 within the first twelve (12) months of the Initial Term of this Agreement. [³⁷⁶]

9 Even before the sale was finalized, and as recommended by Carson, Harrison formed a
10 "DaVinci Taskforce" (which was later renamed "Da Vinci Steering Committee").³⁷⁷ On the
11 Committee were several of the surgeons who had written letters in support of the robot at
12 Carson's behest, including Dr. Bildsten.³⁷⁸ These were also many of the surgeons who would
13 receive Harrison's free training slots (including Dr. Bildsten).

14 ISI's Dave Carson, Sean O'Connor, and Damon Daniels attended the Task
15 Force/Steering Committee.³⁷⁹ All three salesmen were supervised by Glenn Vavoso, who
16 worked out of ISI's headquarters in California.³⁸⁰ And the Commission Plans of all three
17 salesmen were, at ISI's demand, "governed by the laws of the State of California."³⁸¹

18 After the first meeting, O'Connor privately "expressed some doubt about the potential
19 quality" of Harrison's robotics program to Carson.³⁸² Carson reminded O'Connor "not to
20 communicate any bias against Harrison" because "Hospitals like Harrison are our future."³⁸³

21 ³⁷⁶ PT-110 at 30627.

22 ³⁷⁷ PT-82.

23 ³⁷⁸ PT-82.

³⁷⁹ PT-82.

³⁸⁰ Exhibit K to Mullenix Declaration (Carson Deposition) at 20:12-21:2; Exhibit B to Mullenix
Declaration (Nagel Deposition) at 12:17-25.

³⁸¹ PT-221 at 34227; PT-210 at 34338; PT-261 at 34257.

³⁸² PT-188.

³⁸³ PT-188.

1 He warned O'Connor that his concerns "shouldn't extend beyond you and me."³⁸⁴

2 In the meantime, the Committee had to decide credentialing criteria for robotic surgery
3 at Harrison. No one on the Committee had any experience as a robotic surgeon. As one of the
4 non-physician members of the Committee, Mickey Sanders, put it: "we had nothing to start
5 with, and so ... we were looking to the reps ... to tell us what is the community standard in the
6 other hospitals[.]"³⁸⁵ Sanders said that ISI's representatives first provided the Committee with
7 the Clinical Pathway Document—the document that sets a standard of "2 Cases or Hospital
8 Protocol." According to Sanders: "That was kind of ... where we started[.]"³⁸⁶ As Sanders
9 continued to gather information on credentialing criteria, there continued to be "input from the
10 da Vinci rep[.]"³⁸⁷ According to the Steering Committee notes, this input included "samples of
11 credentialing criteria" provided to Sanders by ISI's O'Connor or Carson.³⁸⁸

12 The following week, Sanders presented draft Credentialing Criteria to the Committee
13 which, in every material respect, mirrored the ISI Clinical Pathway Document.³⁸⁹ These
14 criteria were later adopted.³⁹⁰ Under the adopted criteria, Dr. Bildsten would not be allowed to
15 perform robotic surgery until he had "documented successful completion of the hands-on
16
17

18 ³⁸⁴ PT-188.

19 ³⁸⁵ Exhibit N to Mullenix Declaration (Sanders Deposition) at 26:20-25.

20 ³⁸⁶ Exhibit N to Mullenix Declaration (Sanders Deposition) at 28:19-21; 27:17-21.

21 ³⁸⁷ Exhibit N to Mullenix Declaration (Sanders Deposition) at 33:13-17; 40:23-41:3 ("Q. And
22 there was an earlier minute that we looked at from one of the earlier meetings where Mr. Carson
23 or one of the Intuitive reps was going to get you material on credentialing. Did they ultimately
do that? A. They did, but could I -- I couldn't sit here and tell you in what form it was, was it
conversation, documents.").

³⁸⁸ PT-82.

³⁸⁹ PT-83; PT-229 (Bildsten Credentialing Application) at BATES 50158-50159; compare with
PT-42 (Clinical Pathway).

³⁹⁰ See PT- 262 (Bildsten Credentialing Application).

1 training ... required by the manufacturer.”³⁹¹ This was the training that ISI offered him in
2 Sunnyvale, California.³⁹²

3 Another issue confronting the Committee was whether to get a new operating table for
4 urology procedures. The Committee had money in its budget for a new table if necessary, and
5 wanted to assure that any table it bought “can better accommodate obese patients.”³⁹³ On June
6 20, 2008, Dave Carson emailed Harrison’s Director of Surgical Services to confirm that “any
7 table will work” with the robot.³⁹⁴ Under this assurance, Harrison elected to not to buy a new
8 table.

9 ISI also convinced Harrison through the Steering Committee process to make one of its
10 staff members, Perla Lapidario, a dedicated da Vinci “robotics coordinator.” ISI even brought
11 Ms. Lapidario to California for training as robotics coordinator.³⁹⁵

12 By the July 1 Steering Committee meeting, Carson was ready to hand the Harrison
13 Steering Committee over to the “clinical team” of Damon Daniels (the CSR who would work
14 directly with Harrison’s surgeons) and Sean O’Connor (Daniels’s supervisor).³⁹⁶ At that
15 meeting, according to Carson, Daniels and O’Connor “really established themselves as
16 experts.”³⁹⁷ They did so by again reinforcing the need for surgeons to “commit” to the Clinical
17 Pathway.³⁹⁸ They also did so by presenting ISI’s “marketing toolkit,” which ISI provided to
18 hospitals as part of the sale. The toolkit included numerous marketing resources that would
19

20 ³⁹¹ Exhibit Q to Mullenix Declaration (Bildsten Deposition) at 53:25-54:8.

21 ³⁹² Exhibit Q to Mullenix Declaration (Bildsten Deposition) at 54:6-8.

22 ³⁹³ PT-82 at 2.

23 ³⁹⁴ See PT-186, PT-187.

³⁹⁵ Exhibit R to Mullenix Declaration (Lapidario Deposition) at 23:9-23.

³⁹⁶ See PT-84; see also PT-191.

³⁹⁷ PT-191.

³⁹⁸ See PT-118 at 30808; PT-84.

1 allow ISI to help the hospital market da Vinci surgery to nearby patients.³⁹⁹ Included in these
2 resources were ISI brochures designed to tell potential patients: “Your doctor is one of the
3 growing number of surgeons worldwide who’s been *successfully trained* in providing leading-
4 edge treatments *such as da Vinci Prostatectomy*.”⁴⁰⁰

5 Finally, at the July 1 meeting, ISI presented a three-page implementation timeline for
6 the da Vinci program at Harrison.⁴⁰¹ The plan ISI presented included detailed entries,
7 complete with dates and persons responsible, for every step ISI suggested Harrison take,
8 including the date credentials should be decided, install dates for the robot, the date the proctor
9 would be scheduled for the first case, the date a “Core Four” staff team would be selected, the
10 dates the surgeons would discuss the Clinical Pathway, and numerous other scheduled events.

11 According to the implementation timeline, the conversation with Dr. Bildsten and
12 Damon Daniels regarding the Clinical Pathway should have taken place on July 2, 2008.⁴⁰² If
13 the conversation did take place that day, then Daniels should have learned by that day that it
14 would be impossible, given the patient volume of Dr. Bildsten’s urology practice, for Dr.
15 Bildsten to meet the procedure volume requirements of the Clinical Pathway. For instance, Dr.
16 Bildsten had completed only approximately 100 prostatectomy procedures in the 16 years since
17 beginning his residency in 1992.⁴⁰³ Thus, Dr. Bildsten could not be reasonably expected to be
18 able to pick and choose “simple cases” with “Low BMI” if he was also to follow ISI’s
19

20 ³⁹⁹ PT-118 at 30820 (“Integrated Marketing Implementation Plan, Print Ad Samples &
21 Templates, Website Samples & Templates, Television Ad B-Roll, Patient Education Videos,
22 Patient Hospital Posters, Patient Education Brochures & Seminars, and Referring Physician
23 Seminar” materials).

⁴⁰⁰ PT-152 at 2 (emphasis added).

⁴⁰¹ PT-121.

⁴⁰² PT-121 at 30838.

⁴⁰³ Exhibit Q to Mullenix Declaration (Bildsten Deposition) at 42:21-43:13.

1 instruction to perform “one case per week in order to get through the learning curve as quickly
2 as possible.”⁴⁰⁴ He simply did not have enough patients to be selective *and* follow the
3 Pathway.

4 Even so, Dr. Bildsten committed to Daniels to follow the pathway.⁴⁰⁵ Dr. Bildsten
5 traveled to California for his one-day training at the porcine lab on July 17, 2008.⁴⁰⁶ Damon
6 Daniels traveled to California with Dr. Bildsten for training.⁴⁰⁷ He did so to give Dr. Bildsten
7 “a sense of comfort.”⁴⁰⁸

8 Because of the changes Mr. Nagel had made years prior, Dr. Bildsten received almost
9 none of the training or assessment ISI had first promised to the FDA.

10 It is unclear what Dr. Bildsten did in the way of further training between his Sunnyvale
11 training and his first procedures, which took place on July 28-29, 2008. Damon Daniels
12 testified that surgeons will generally do some practice with him in the week leading up to their
13 first procedures, though he had no specific recollection of Dr. Bildsten engaging in such
14 practice.⁴⁰⁹ Daniels explained that surgeons get value from this practice because, despite the
15 fact that they have already been “certified” by ISI at the Sunnyvale training, they still have
16 many questions about how to work the robot. Regardless, Daniels testified that Dr. Bildsten
17 never refused any request Daniels ever made of him regarding training.⁴¹⁰

18 Dr. Bildsten’s first two procedures were proctored by a doctor from Tennessee.⁴¹¹ The
19

20 ⁴⁰⁴ PT-42.

⁴⁰⁵ Exhibit A to Mullenix Declaration (Daniels Deposition) at 259:13-18; 231:23-25.

21 ⁴⁰⁶ PT-41 at 319.

⁴⁰⁷ Exhibit A to Mullenix Declaration (Daniels Deposition) at 39:15-40:2.

22 ⁴⁰⁸ Exhibit A to Mullenix Declaration (Daniels Deposition) at 40:5-9.

⁴⁰⁹ Exhibit A to Mullenix Declaration (Daniels Deposition) at 180:20-181:7.

23 ⁴¹⁰ Exhibit A to Mullenix Declaration (Daniels Deposition) at 214:21-24.

⁴¹¹ PT-96, PT-94.

1 proctor was arranged by Daniels through ISI's California-based Training Department,⁴¹² and
2 Dr. Bildsten had no choice in who would be his proctor.⁴¹³ (ISI required its proctors to agree
3 that California law would govern any disputes between ISI and the proctors.⁴¹⁴) Harrison paid
4 a proctor fee to ISI, and the proctor was then paid by a check from ISI.⁴¹⁵ A traditional open
5 prostatectomy in the hands of an experienced surgeon would take 2.5 hours.⁴¹⁶ ISI trained its
6 sales persons to tell surgeons who were reluctant to adopt da Vinci that "most da Vinci
7 surgeons today perform quality radical prostatectomy procedures in less than two hours." Dr.
8 Bildsten's first two robotic procedures took 9.5 and 7.5 hours respectively,⁴¹⁷ despite the fact
9 that both patients were relatively easy patients.⁴¹⁸

10 ISI has produced no records to reflect any training or assessment of Dr. Bildsten's skills
11 during or following those two proctored procedures. There is no evidence that Daniels
12 suggested any "advanced" or additional training to Dr. Bildsten following these procedures.
13 Dr. Bildsten did not have another opportunity to perform any prostatectomy, robotic or open,
14 until Fred Taylor's surgery on September 9, 2008.⁴¹⁹

17 _____
18 ⁴¹² Exhibit A to Mullenix Declaration (Daniels Deposition) at 49:7-50:2.

19 ⁴¹³ Exhibit Q to Mullenix Declaration (Bildsten Deposition) at 157:11-13.

20 ⁴¹⁴ Exhibit J to Mullenix Declaration (Lohrasbi Deposition) at 63:22-64:15.

21 ⁴¹⁵ Exhibit J to Mullenix Declaration (Lohrasbi Deposition) at 30:19-25. The hospital would
22 have to pay ISI \$1,000 for the proctor's travel expenses, even if those travel expenses did not
23 total \$1,000. The proctor received reimbursement from ISI only for his actual travel expenses.
Id. at 59:2-60:4.

⁴¹⁶ PT-93 at 3263.

⁴¹⁷ PT-94.

⁴¹⁸ Exhibit Q to Mullenix Declaration (Bildsten Deposition) at 139:25-140:15.

⁴¹⁹ PT-265 (Plaintiffs' Third Set of Interrogatories and Second Set of Requests for Production
Propounded to Defendant Scott Bildsten, DO, with Responses) at RFP No. 39 (July 28, 2008-
September 9, 2008).

1 **M. The Taylor Surgery: Dr. Bildsten's first non-proctored procedure.**

2 Fred Taylor had a biopsy sample diagnosed with prostate cancer on August 16, 2008.⁴²⁰
3 He was 67 years old, had undergone coronary artery bypass graft surgery six years prior, and
4 had undergone an umbilical hernia repair with mesh before that.⁴²¹ He was obese, with a BMI
5 of 39. Even so, he was in good general health and would fish, swim, and golf.⁴²²

6 Open prostatectomy, the type of surgery that Dr. Bildsten had performed his entire
7 career, is "routinely performed for localized prostate cancer, with excellent results and minimal
8 morbidity."⁴²³ Dr. Bildsten had never had a complication during an open prostatectomy.⁴²⁴ *da*
9 *Vinci* Prostatectomy, on the other hand, is far more difficult for new robotic surgeons to safely
10 perform. For instance, surgeons early in their *da Vinci* learning curve face the danger that the
11 surgery will take a very long time.

12 ISI had trained Damon Daniels to believe that Bildsten had learned "all necessary
13 skills" to perform *da Vinci* Prostatectomy. It had trained and authorized Daniels to "partner"
14 with surgical teams "to review and select appropriate cases." It had financially incentivized
15 Daniels to try to convince surgeons to perform *every* prostatectomy with the robot. It had not
16 trained him to seek a proctor for particularly challenging cases,⁴²⁵ and Daniels recognized that
17 the necessity of a proctor (at \$3,000 per surgery) can make it more difficult to convince
18 surgeons to perform surgeries with the robot.⁴²⁶ This problem is such an impediment to a
19

20 ⁴²⁰ PT-263 at 100120 (9/5/2008 Surgical Note).

21 ⁴²¹ PT-263 at 100120 (9/5/2008 Surgical Note).

22 ⁴²² Exhibit S to Mullenix Declaration (Josette Taylor Deposition) at 55:10-56:7, 81:17-85:12,
85:14-90:3.

23 ⁴²³ PT-93 at 3262.

⁴²⁴ Exhibit Q to Mullenix Declaration (Bildsten Deposition) at 134:20-22.

⁴²⁵ Exhibit A to Mullenix Declaration (Daniels Deposition) at 283:1-12.

⁴²⁶ Exhibit A to Mullenix Declaration (Daniels Deposition) at 245:17-246:4.

1 CSR's ability to meet his procedure quota that one ISI manager even explicitly ordered his
2 CSRs: "Don't let proctoring or credentialing get in our way."⁴²⁷ Thus, Daniels never made any
3 attempt to even suggest that Bildsten have a proctor for the Taylor surgery.⁴²⁸ Rather, with
4 Daniels as his "partner," Dr. Bildsten decided to use the robot for the Taylor surgery.

5 The Taylor surgery took place on September 9, 2008. Though no surgeon proctor was
6 present, Damon Daniels *was* present in the operating room for the surgery. Daniels believed it
7 was his "responsibility" to "be there to help" the surgeons in the operating room, and he told
8 the doctors as much.⁴²⁹ According to Daniels, the device is so complex that questions remain
9 even after (1) physicians have been trained and certified by ISI, (2) the staff has gone through
10 an in-service with the CSR, (3) hospital credentialing requirements have been satisfied, (4) the
11 surgeons have had additional practice with the robot, (5) the surgical team has had a dry run of
12 the procedure, and (6) the surgeon has successfully completed two proctored surgeries:

13 It's a lot -- it's an intricate device. It is a lot of stuff. I mean, it's not just one
14 instrument taken in and fire it, and then you're done. There's a lot of hand
15 movements. There's a clutch. There's a camera. There's things to control that you
16 need to be comfortable with, and it takes some time to do that. There's a lot of
17 stuff to remember. And you know, after -- after those things you just mentioned,
18 you know, it's not that easy to remember everything.^[430]

19 One of ISI's proctors offered a similar assessment, testifying that the ISI representatives
20 are present in the operating room "for the first couple hundred cases" because the robot is such
21 a "complex machine."⁴³¹ In fact, when he was asked whether "it would be safe" for a surgeon
22 to perform an unsupervised surgery without a proctor *or* a CSR there, the response by Daniels

23 ⁴²⁷ PT-99.

⁴²⁸ Exhibit A to Mullenix Declaration (Daniels Deposition) at 284:2-6.

⁴²⁹ Exhibit A to Mullenix Declaration (Daniels Deposition) at 206:5-24.

⁴³⁰ Exhibit A to Mullenix Declaration (Daniels Deposition) at 302:1-303:12.

⁴³¹ Exhibit J to Mullenix Declaration (Lohrasbi Deposition) at 78:20-21.

1 was: "I would prefer to be there."⁴³²

2 With no proctor present, preventable errors were made from the start. First, Bildsten
3 began the surgery by "insufflating" (inflating) Mr. Taylor's abdomen at "20mmHg
4 pressure."⁴³³ An unnecessarily high level of pressure exacerbates the harmful effects of a long
5 surgery:

6 Insufflation pressures as high as 20 can cause renal failure. They can cause
7 decreased cardiac output. They can cause ventilatory profusion and ventilation
8 mismatches in the lung. The increased intra-abdominal pressure can push CO2
9 into veins and cause an increase in end title CO2. They can cause acidosis.^[434]

10 After Mr. Taylor was insufflated, it became clear that the operating table ISI had earlier
11 recommended was actually unable to accommodate Fred Taylor, due to his size, in the proper
12 "extreme Trendelenburg" position.⁴³⁵ Daniels attempted to fix the problem by removing x-ray
13 cassettes from the table to lower it, but even then the robot could not get over Mr. Taylor's
14 abdomen.⁴³⁶ As a result, Mr. Taylor "had to be flattened out to just only slight Trendelenburg"
15 in order for the robot to "dock."⁴³⁷

16 "Ideal patient positioning" is necessary to prevent nerve damage during robotic
17 prostatectomy due to "the potential for long operative times at the beginning of the learning
18 curve[.]"⁴³⁸ Use of the "slight Trendelenburg" position decreases visibility, further prolonging
19 the surgery.⁴³⁹ The longer the surgery, the greater the risk of rhabdomyolosis⁴⁴⁰ and excessive

20 ⁴³² Exhibit A to Mullenix Declaration (Daniels Deposition) at 303:13-20.

⁴³³ PT-252 (Operative Note).

⁴³⁴ Exhibit D to Mullenix Declaration (Ramin Deposition) at 108:15-20.

⁴³⁵ PT-252 (Operative Note).

⁴³⁶ *Id.*

⁴³⁷ *Id.*

⁴³⁸ Exhibit J to Mullenix Declaration (Lohrasbi Deposition) at 101:18-102:1.

⁴³⁹ Exhibit D to Mullenix Declaration (Ramin Deposition) at 122:4-8.

⁴⁴⁰ Exhibit J to Mullenix Declaration (Lohrasbi Deposition) at 81:8-82:3; 85:22-25.

1 blood loss.⁴⁴¹ Because Bildsten had not been trained about the dangers of proceeding without
2 placing Mr. Taylor in steep Trendelenburg, and because Daniels did not warn Bildsten about
3 those dangers,⁴⁴² the surgery continued.

4 At this point, Dr. Bildsten had not even gotten "on console," meaning he had not yet
5 taken the controls of the robot, even though Mr. Taylor had already been in the operating room
6 and under anesthesia for over two hours.⁴⁴³ The trouble continued, however, as Dr. Bildsten
7 quickly discovered "a moderate amount of intestines still covering the lower pelvis."⁴⁴⁴ Dr.
8 Bildsten did his best to proceed with the surgery robotically, but "it was difficult to maintain
9 good vision for the posterior bladder neck dissection due to the intestinal contents continually
10 getting into the visual field."⁴⁴⁵ Dr. Bildsten continued for "several hours of trying to get better
11 visualization,"⁴⁴⁶ but eventually decided to abandon the use of the robot. After Mr. Taylor had
12 been in the operating room for eight hours and fifty minutes, the robot was finally undocked.⁴⁴⁷

13 By the time Dr. Bildsten undocked the robot, Mr. Taylor had already lost almost 1800
14 milliliters (7.6 cups) of his blood.⁴⁴⁸ And because Dr. Bildsten had already performed several
15 of the procedural steps in the prostatectomy at that time, simply closing Mr. Taylor up at that
16 point was not a safe option. He had to finish the prostatectomy, despite the fact that Mr. Taylor
17 had already been under anesthesia for nine hours. This required a new, six inch incision, in
18
19

20 ⁴⁴¹ Exhibit J to Mullenix Declaration (Lohrasbi Deposition) at 106:7-18.

21 ⁴⁴² PT-266 (ISI's Answers to Plaintiff's Second Requests for Production).

22 ⁴⁴³ PT-264 (Lapidario Timeline).

23 ⁴⁴⁴ PT-252 (Operative Note).

⁴⁴⁵ PT-252 (Operative Note).

⁴⁴⁶ PT-252 (Operative Note).

⁴⁴⁷ PT-264 (Lapidario Timeline).

⁴⁴⁸ PT-264 (Lapidario Timeline).

1 addition to the five existing "port" holes in Mr. Taylor's abdomen.⁴⁴⁹

2 Unfortunately, another problem was soon discovered: a two centimeter "tear" in the
3 lower rectum.⁴⁵⁰ The tear was not discovered until Mr. Taylor had been in the operating room
4 for ten hours and 36 minutes.⁴⁵¹ Dr. Bildsten, upon discovering the tear, obtained an
5 "intraoperative consult" from general surgeon Greg Fleischhauer.⁴⁵² Dr. Fleischhauer worked
6 to surgically repair the tear, further extending the length of the surgery.⁴⁵³

7 ISI takes the position in its summary judgment brief that this tear was actually caused
8 by Dr. Bildsten's finger, during the open part of the procedure.⁴⁵⁴ That position is directly
9 contradicted by robotic urology expert Adam Ramin, M.D.:

10 Q Is it your opinion that it occurred during the da Vinci portion of the
11 procedure before opening?

12 A Yes.

13 Q How did that happen?

14 A This is a portion where they were trying to again develop the
15 Denonvillier's fascia. And based on his operative report he said after several
16 hours of trying to develop this area, they decided to convert to open surgery.
17 This is an area which has a high risk of cutting into the rectum and not
18 recognizing it. The rectum is only a few millimeters away from the
19 Denonvilliers' fascia in this particular area. And if you have more visualization,
20 if there is blood coming into the field and bowel is coming into the field, add it to
21 physician's fatigue, add it to a certain level of frustration, and add it to a patient
22 not being in a correct position, it's very hard to tell whether you're properly --
23 you are in the proper space or not. Very high chance that the rectum is injured at

18 ⁴⁴⁹ PT-252 (Operative Note).

19 ⁴⁵⁰ PT-252 (Operative Note).

20 ⁴⁵¹ PT-264 (Lapidario Timeline).

21 ⁴⁵² PT-252 (Operative Note).

22 ⁴⁵³ PT-252 (Operative Note).

23 ⁴⁵⁴ See ISI's Motion for Summary Judgment on All Claims at 11 (relying on Dr. Bildsten's deposition testimony to support its claim that "[t]he rectal injury occurred after the da Vinci system had already been turned off, disconnected from Mr. Taylor, removed from the surgical field, and was sitting unused in the operating room."); see also Exhibit Q to Mullenix Declaration (Bildsten Deposition) at 275:18-20 ("And I believe my finger slipped into -- you know, went into his rectum and caused the tear that was there.").

1 that point.⁴⁵⁵

2 The general surgeon that Dr. Bildsten asked to repair the tear also casts significant doubt on
3 ISI's "finger tear" theory. Dr. Fleischhauer testified at his deposition that the tear "looked
4 clean," not "ragged."⁴⁵⁶ He further testified that the tear looked like "it was a surgical
5 instrument ... that made the laceration."⁴⁵⁷

6 Regardless, after Dr. Fleischhauer repaired the tear, Dr. Bildsten still had to finish the
7 procedure. Because it is necessary to slice through the urethra to remove the prostate (which
8 surrounds the urethra like a donut), the final step of the surgery requires reconnecting the two
9 sections. This process is called "anastomosis." "[W]atertight anastomosis is key to preventing
10 urinary complications" in robotic surgery.⁴⁵⁸ Watertight anastomosis is particularly important
11 in robotic prostatectomy because, unlike in a traditional open procedure, robotic prostatectomy
12 requires the arms of the robot to open the peritoneum.⁴⁵⁹ Thus, in robotic prostatectomy: "The
13 stakes are higher" with respect to achieving watertight anastomosis.⁴⁶⁰ Dr. Bildsten,
14 unfortunately, had not been trained by ISI to understand that opening of the peritoneum
15 required watertight anastomosis, something not required in an open procedure, and he did not
16 perform a watertight anastomosis on Mr. Taylor.⁴⁶¹ That failure directly contributed to several
17 of Mr. Taylor's later complications.⁴⁶²

18 After 13 hours and 26 minutes, the surgery was finally considered "finished."⁴⁶³ Even

19
20 ⁴⁵⁵ Exhibit D to Mullenix Declaration (Ramin Deposition) at 79:10-80:3.

⁴⁵⁶ Exhibit T to Mullenix Declaration (Fleischhauer Deposition) at 59:4-7.

⁴⁵⁷ Exhibit T to Mullenix Declaration (Fleischhauer Deposition) at 59:8-19.

⁴⁵⁸ Exhibit J to Mullenix Declaration (Lohrasbi Deposition) at 108:17-109:23.

⁴⁵⁹ Exhibit D to Mullenix Declaration (Ramin Deposition) at 104:10-105:3.

⁴⁶⁰ Exhibit D to Mullenix Declaration (Ramin Deposition) at 104:10-105:3.

⁴⁶¹ Exhibit Q to Mullenix Declaration (Bildsten Deposition) at 257:12-258:14.

⁴⁶² Exhibit D to Mullenix Declaration (Ramin Deposition) at 105:8-20.

⁴⁶³ PT-264 (Lapidario Timeline).

1 so, Fred Taylor remained in the operating room as his surgeons waited for an ambulance to
2 arrive so he could be transported from Harrison's Silverdale facility to its Bremerton facility,
3 which had an intensive care unit.⁴⁶⁴ Nearly 15 hours after he first entered the operating room
4 for his "minimally invasive surgery," he was intubated in an ambulance.

5 The weeks and months to come showed that the results of the surgery were devastating.
6 ISI does not even dispute that, because of the surgery, Mr. Taylor lost 3500 cubic centimeters
7 (almost 15 cups) of blood,⁴⁶⁵ had to have 7500 cubic centimeter "volume replacement,"⁴⁶⁶ and
8 underwent a consequent hypovolemic shock.⁴⁶⁷ Nor does ISI dispute that the effects of the
9 extraordinarily long surgery also caused Mr. Taylor to suffer from acute renal failure (kidney
10 failure),⁴⁶⁸ encephalopathy (impaired brain function),⁴⁶⁹ acute rhabdomyolysis (break down in
11 muscle tissue),⁴⁷⁰ critical illness myopathy (muscle disease),⁴⁷¹ urethral anastomotic leak (non-
12 watertight urethra),⁴⁷² femoral nerve injury,⁴⁷³ stroke,⁴⁷⁴ acute respiratory failure,⁴⁷⁵ metabolic
13 acidosis (abnormally acidic body fluids),⁴⁷⁶ severe urethral contracture (shortened urethra),⁴⁷⁷
14 pleural effusions (fluid on the lungs),⁴⁷⁸ and permanent incontinence.⁴⁷⁹ He also suffered a one-

16 ⁴⁶⁴ PT-264 (Lapidario Timeline).

17 ⁴⁶⁵ PT-248 (ISI's Response to Plaintiffs' First Requests for Admission) at RFA 9.

18 ⁴⁶⁶ PT-248 (ISI's Response to Plaintiffs' First Requests for Admission) at RFA 15.

19 ⁴⁶⁷ PT-248 (ISI's Response to Plaintiffs' First Requests for Admission) at RFA 19.

20 ⁴⁶⁸ PT-248 (ISI's Response to Plaintiffs' First Requests for Admission) at RFA 10.

21 ⁴⁶⁹ PT-248 (ISI's Response to Plaintiffs' First Requests for Admission) at RFA 11.

22 ⁴⁷⁰ PT-248 (ISI's Response to Plaintiffs' First Requests for Admission) at RFA 12.

23 ⁴⁷¹ PT-248 (ISI's Response to Plaintiffs' First Requests for Admission) at RFA 21.

⁴⁷² PT-248 (ISI's Response to Plaintiffs' First Requests for Admission) at RFA 13.

⁴⁷³ PT-248 (ISI's Response to Plaintiffs' First Requests for Admission) at RFA 16.

⁴⁷⁴ PT-248 (ISI's Response to Plaintiffs' First Requests for Admission) at RFA 17.

⁴⁷⁵ PT-248 (ISI's Response to Plaintiffs' First Requests for Admission) at RFA 18.

⁴⁷⁶ PT-248 (ISI's Response to Plaintiffs' First Requests for Admission) at RFA 20.

⁴⁷⁷ PT-248 (ISI's Response to Plaintiffs' First Requests for Admission) at RFA 24.

⁴⁷⁸ PT-248 (ISI's Response to Plaintiffs' First Requests for Admission) at RFA 26.

⁴⁷⁹ PT-248 (ISI's Response to Plaintiffs' First Requests for Admission) at RFA 25.

1 inch tear of his rectum during the surgery. ISI does not dispute that this tear caused him to further
2 suffer a colouethral fistula (abnormal hole through his colon) and gram negative sepsis (bacterial
3 infection).

4 Nine days after the robotic surgery, the repair of the rectal tear had broken down. The
5 repair required another surgery and a diverting colostomy. He was not finally extubated until 17
6 days after the robotic surgery. Five months after the robotic surgery, he had another procedure to
7 begin repairing urinary problems. Ten months after the robotic surgery, he had a surgical
8 implantation of an "artificial urinary sphincter" because he was still "totally incontinent of urine."
9 11 months after the robotic surgery, he had another surgery to reverse the earlier colostomy. A
10 year after the robotic surgery, he had another surgery to repair the artificial urinary implant. The
11 stresses from these numerous injuries and procedures left Mr. Taylor largely sedentary, which
12 further increased the stresses on his heart. He succumbed to heart failure and died on August 25,
13 2012. The pathologist who performed his autopsy concluded that "the enormous stress" placed on
14 Mr. Taylor's already diseased heart by the 2008 da Vinci Prostatectomy placed "additional severe
15 demands" on Mr. Taylor's heart.⁴⁸⁷ For that reason, Mr. Taylor's death was "a direct and
16 proximate result of the complications of his robotic surgery on September 9, 2008."⁴⁸⁸

17
18 **N. Dr. Bildsten gives up on robotic surgery.**

19 Dr. Bildsten has stopped using robots to perform surgery. Though ISI tried to convince
20 him to continue as a robotic surgeon, even sending him again to California for additional
21
22

23 ⁴⁸⁷ Declaration of William J. Brady at 4:16, 4:24.

⁴⁸⁸ *Id.* at 5:8-10.

1 training,⁴⁸⁹ he gave up robotics forever in early 2009.⁴⁹⁰ Dr. Bildsten testified that robotic
2 surgery was simply too difficult to learn to be worthwhile:

3 I was under the initial impression you would get a level of comfort within a
4 certain number of cases. And as the -- as it went along, it seemed it was going to
5 be much longer than that. . . . And after speaking with some other urologists in a
6 similar situation who attempted to use the robotic -- the da Vinci robot for
prostatectomy, a lot of others have decided not to proceed, as well. They found
the learning curve so steep and lengthy that the level of comfort just took too
long and decided to quit. And I was one of those.^[491]

7 Dr. Bildsten has also since explained that, when he first agreed to train with ISI, he believed that
8 "the ISI training program had been approved by the FDA."⁴⁹² He also believed, based on his
9 conversations with ISI representatives, "that ISI training and two proctored surgeries was
10 sufficient to achieve basic competency and safely perform unsupervised robotic surgeries."⁴⁹³ He
11 explained at his deposition that, looking back, more proctored surgeries were necessary: "With the
12 advantage of looking back, I would prefer to have more proctored cases a minimum of five,
13 but possibly ten[.]"⁴⁹⁴ Bildsten explained that having a proctor present not only provides the
14 advantage of that proctor's experience and knowledge, it also reduces the pressure on the novice
15 surgeon: "As you're doing the procedure and you realize that you're really the only one in the
16 vicinity that's qualified to use the robot, you're sort of out there on an island a little bit."⁴⁹⁵

17 Dr. Bildsten believes he "likely would not have agreed to begin training on the robot" if he
18 had been accurately informed about the amount of time to reach basic competency.⁴⁹⁶ He believes
19 if he had simply performed an open procedure on Mr. Taylor, "there may have been no

20 ⁴⁸⁹ Exhibit Q to Mullenix Declaration (Bildsten Deposition) at 153:7-11.

⁴⁹⁰ Exhibit Q to Mullenix Declaration (Bildsten Deposition) at 29:20-21.

21 ⁴⁹¹ Exhibit Q to Mullenix Declaration (Bildsten Deposition) at 29:22-30:14.

⁴⁹² Bildsten Declaration at ¶3.

22 ⁴⁹³ Bildsten Declaration at ¶4.

⁴⁹⁴ Exhibit Q to Mullenix Declaration (Bildsten Deposition) at 181:17-25.

23 ⁴⁹⁵ Exhibit Q to Mullenix Declaration (Bildsten Deposition) at 182:17-21.

⁴⁹⁶ Bildsten Declaration at ¶6.

1 complications” and Mr. Taylor’s injuries, “if any, would have been significantly less.”⁴⁹⁷ Had he
2 been informed about the dangers of insufflation “at levels over 15 millimeters of mercury,” or
3 of “the need to ensure a watertight urethral anastomosis,” he would have “conducted the Taylor
4 surgery differently, in a way that would have reduced the risk of harm to Mr. Taylor.”⁴⁹⁸

5 III. STATEMENT OF ISSUES

6 1. Does the Washington Product Liability Act preempt negligence claims unrelated
7 to the design, manufacture or distribution of a product?

8 2. Is there a genuine factual dispute about whether ISI undertook or assumed a duty
9 to train Dr. Bildsten to perform robotic prostatectomies?

10 3. Is there a genuine factual dispute about whether ISI breached its assumed duty to
11 train Dr. Bildsten with reasonable care?

12 4. Is there a genuine factual dispute as to whether ISI provided negligent warnings
13 under the WPLA?

14 5. Is there a genuine factual dispute as to whether ISI’s conduct was a substantial
15 factor in causing Mr. Taylor’s injuries?

16 IV. LEGAL AUTHORITY AND ARGUMENT IN OPPOSITION TO ISI’S MOTION 17 FOR SUMMARY JUDGMENT

18 A. Summary Judgment Standard

19 Summary judgment is not appropriate unless “the pleadings, depositions, answers to
20 interrogatories, and admissions on file, together with the affidavits, if any, show that there is no
21 genuine issue as to any material fact and that the moving party is entitled to a judgment as a
22 matter of law.” CR 56(c). ISI, as the moving party, “bears the initial burden of showing the

23 ⁴⁹⁷ Bildsten Declaration at ¶7.

⁴⁹⁸ Bildsten Declaration at ¶9.

1 absence of an issue of material fact.” *Young v. Key Pharmaceuticals, Inc.*, 112 Wn.2d 216, 225,
2 770 P.2d 182, 187 (1989). If ISI carries this initial burden, Mrs. Taylor must make a sufficient
3 showing to establish the existence of at least a factual issue regarding any challenged element of
4 her claims. *Id.* In making her response, Mrs. Taylor “cannot rely on the allegations made in its
5 pleadings” but must set forth by affidavits or otherwise, specific facts showing that there is a
6 genuine issue for trial. *Id.*, at 225-26. “A material fact is one upon which the outcome of the
7 litigation depends.” *Clements v. Travelers Indem. Co.*, 121 Wn.2d 243, 249, 850 P.2d 1298, 1301
8 (1993). “All facts are considered in the light most favorable to the nonmoving party,” here, Mrs.
9 Taylor, and “summary judgment is granted only if, from all of the evidence, reasonable persons
10 could reach but one conclusion.” *Vallandigham v. Clover Park School Dist. No.400*, 154 Wn.2d
11 16, 26 109 P.3d 805, 810 (2005).

12 **B. Mrs. Taylor Is No Longer Stating Claims for Design Defect, Manufacturing**
13 **Defect, Breach of an Express or Implied Warranty, Breach of Contract, or**
14 **Violation of Washington’s Consumer Protection Act.**

15 Mrs. Taylor clarifies that she is not claiming that the da Vinci surgical system was
16 defectively designed or that some defect in the robot itself was introduced in the manufacturing
17 process. She is also no longer pursuing a claim for breach of an express or implied warranty or
18 for breach of contract. Mrs. Taylor is also no longer stating a claim under Washington’s
19 Consumer Protection Act.

20 **C. WPLA Does Not Preempt Negligence Claims Unrelated to the Design,**
21 **Manufacture, or Sale of the Product.**

22 ISI claims that all common law negligence claims against it are preempted because it is a
23 product manufacturer and distributor. This is incorrect. The Washington Product Liability Act
24 (“WPLA”) preempts common law *product liability claims*, whether based in strict liability or
25 negligence. It does not preempt all common law claims against a defendant that happens to be a

1 product manufacturer for activity other than its manufacture and distribution of the product. It is
2 the nature of the claim, not the nature of the defendant, that controls. As a result, Mrs. Taylor's
3 claims against ISI for negligently training Dr. Bildsten and representing its training as sufficient
4 are not preempted.

5 The Washington Supreme Court held that the WPLA preempted common law *product*
6 *liability claims* in *Washington Water Power Co. v. Graybar Elec. Co.*, 112 Wn.2d 847, 853, 774
7 P.2d 1199, 1203 (1989). The Court's discussion of preemption and its holding emphasize
8 repeatedly that only common law product liability claims are preempted; nothing in the decision
9 indicates that preemption might apply to all common law claims against a defendant that
10 happened to produce a product:

- 11 • "Two aspects of the WPLA are at issue in this case. First is the extent to which the
12 WPLA preempts traditional common law remedies for product-related harms."
13 112 Wn.2d at 851, 774 P.2d at 1202 (emphasis added).
- 14 • "[I]t is understandable why [the plaintiff] is anxious to preserve the option of
15 bringing product liability claims for economic loss under common law tort
16 theories." 112 Wn.2d at 853, 774 P.2d at 1203 (emphasis added).
- 17 • "[T]he WPLA means nothing if it does not preempt common law product liability
18 claims." *Id.* (emphasis added).
- 19 • "To be sure, the Legislature might have stated its intent to preempt common law
20 product liability claims more certainly than it has in the WPLA." *Id.* (emphasis
21 added).

- 1 • “Our holding that the WPLA preempts the variety of common law causes of action
2 for harms caused by product defects applies also to equitable claims for such
3 harms.” 112 Wn.2d at 855 n.4, 774 P.2d at 1204 n.4 (emphasis added).

4 The *Graybar* Court based its decision largely on the definition of “product liability claim”
5 in RCW 7.72.010(4). That definition further confirms that only common law product liability
6 claims, not all common law claims, are preempted. A product liability claim is defined as

7 any claim or action brought for harm caused by the manufacture, production,
8 making, construction, fabrication, design, formula, preparation, assembly,
9 installation, testing, warnings, instructions, marketing, packaging, storage or
10 labeling *of the relevant product*. It includes, but is not limited to, any claim or
11 action previously based on: Strict liability in tort; negligence; breach of express or
12 implied warranty; breach of, or failure to, discharge a duty to warn or instruct,
13 whether negligent or innocent; misrepresentation, concealment, or nondisclosure,
14 whether negligent or innocent; or other claim or action previously based on any
15 other substantive legal theory except fraud, intentionally caused harm or a claim or
16 action under the consumer protection act, chapter 19.86 RCW.

17 RCW 7.72.010(4) (emphasis added). Thus, a product liability claim is one arising from the
18 defendants’ specific actions regarding the “relevant product”;⁴⁹⁹ it does not include every claim
19 against a defendant which happened to produce a product. The Supreme Court in *Graybar*
20 described the definition of product liability claim as “the operative centerpiece of the statute,
21 linking together the important concepts of ‘claimant’ and ‘harm’ to describe the liabilities of
22 product manufacturers and sellers for product-related injuries.” 112 Wn.2d at 854, 774 P.2d at
23 1204. As it is the textual basis for the Court’s preemption decision, preemption cannot be any
broader than the statutory definition of “product liability claim.”

No court applying Washington law has held that every claim against a product
manufacturer, regardless of the specific theory, must be brought under the WPLA, although a

⁴⁹⁹ “The ‘relevant product’ under this chapter is that product or its component part or parts,
which gave rise to the product liability claim.” RCW 7.72.010(3).

1 number of courts have determined that specific claims are product liability claims which must
2 be brought under the act. *See Washington State Physicians Ins. Exch. & Ass'n v. Fisons Corp.*,
3 122 Wn.2d 299, 323, 858 P.2d 1054, 1066 (1993) (stating that because claim was predicated
4 on alleged failure to warn of dangerous propensities of prescription drug, common law theories
5 were preempted); *Laisure-Radke v. Par Pharmaceutical, Inc.*, 426 F.Supp.2d 1163, 1168-69
6 (W.D. Wash. 2006) (dismissing common law negligence claims relating to side effects of
7 drug); *Macias v. Saberhagen Holdings, Inc.*, 175 Wn.2d 402, 409, 282 P.3d 1069, 1073-74
8 (2012) (“The WPLA is the exclusive remedy for product liability claims. ... *Insofar as a*
9 *negligence claim is product-based*, the negligence theory is subsumed under the WPLA
10 product liability claim.”) (emphasis added).

11 The training ISI provided Bildsten is no more a “product,” than a driver’s education
12 course is a “product.” The WPLA defines a “product” as “any object possessing intrinsic value,
13 capable of delivery either as an assembled whole or as a component part or parts, and produced
14 for introduction into trade or commerce. Human tissue and organs, including human blood and its
15 components, are excluded from this term.” Training is not a product. Because WPLA
16 preemption applies only to product-based claims, Mrs. Taylor’s claims against ISI for its negligent
17 training of Dr. Bildsten are not preempted. These claims sound in negligence, not product
18 liability.

19 If Boeing were to open a flight school at Boeing field to teach pilots how to fly 747s, the
20 actions of its flight school would be subject to common law principles of negligence, not the
21 WPLA. This is true even if it gave free 747 training to a certain number of its customers’
22 employees. If General Motors had an auto manufacturing plant in Washington, and decided to
23

1 also provide loans on its cars to customers, its loan activities would be subject to state lending
2 statutes and common law principles, not the WPLA.

3 Simply stated, ISI could have decided to just sell its robots and leave it to medical schools
4 and hospitals to develop programs for training doctors to operate the equipment and to develop
5 additional procedures in which the equipment could be safely used. If it had done so, ISI would
6 be responsible only for defects in its robotic system or associated warnings and instructions.

7 But ISI did not want to wait to see what training programs, if any, would develop, and
8 what uses, if any, were found for its robotic system. It decided to implement its own training
9 program to prepare as many doctors as possible to use its system. It represented that program as
10 being a “pathway to ensure early success for Robotic Prostatectomy.”⁵⁰⁰ Essentially, ISI opened
11 up a second business in support of its manufacturing business. It recognized that to sell its robots
12 and the associated service and parts, it needed to have more and more surgeons trained to use the
13 system. Hospitals would not buy a da Vinci robot if very few surgeons could use it. And if few
14 hospitals had the system, the number of additional surgeons mastering the system each year would
15 be small. The demand for additional ISI robots, therefore, would also be small. ISI had to “drive
16 the curve.”

17 ISI did so by starting its own training program, in order to prepare more doctors to use its
18 system, and be able to assure hospitals purchasing the system that demand for the robot would
19 increase quickly. While this training program certainly supports ISI’s overall business plan, it is
20 fundamentally different than attaching a warning label or enclosing set of instructions. Therefore,
21 the claim for negligence in completing this undertaking—for providing an inadequate pathway for
22
23

⁵⁰⁰ PT-42 at 42.

1 Dr. Bildsten to take before working on live human beings—is not a product claim, but a common
2 law negligence claim.

3 **D. There Are Material Issues of Fact Regarding Whether ISI Undertook to**
4 **Provide Additional Training to Doctors Interested in Using its Robotic**
5 **System and Whether It Breached that Duty.**

6 By arguing that all claims against it must be product liability claims, ISI essentially argues
7 that its training program is just an extension of its product warnings or instructions. This is the
8 most fundamental fact question in this case. Mrs. Taylor is prepared to show at trial that ISI
9 undertook to do more than just provide instructions on how to operate its machine; it purported to
10 prepare physicians, including doctors like Dr. Bildsten with no prior laparoscopic experience, to
11 perform specific procedures and become “a skilled robotic surgeon.”⁵⁰¹ Unfortunately, ISI did so
12 negligently, telling doctors that they were ready to perform surgeries immediately upon their
13 return from ISI’s training center, and to do so without supervision after only two proctored
14 surgeries, when ISI knew that it has not provided all the training it had represented as appropriate
15 to the FDA, and it knew that the true pathway to safe, effective robotic surgery was much longer.

16 **1. Washington Law Imposes Liability for Negligent Performance of a**
17 **Voluntary Undertaking**

18 Initially, there can be no doubt that under Washington law, a defendant may be liable for
19 negligently performing a task it voluntarily undertakes to perform. One example is the rescue
20 doctrine:

21 One who undertakes, albeit gratuitously, to render aid to or warn a person in danger
22 is required by our law to exercise reasonable care in his efforts, however
23 commendable. If a rescuer fails to exercise such care and consequently increases
the risk of harm to those he is trying to assist, he is liable for any physical damages
he causes.

⁵⁰¹ See PT-42, Exhibit A, at 1.

1 *Brown v. MacPherson's, Inc.*, 86 Wn.2d 293, 299, 545 P.2d 13, 18 (1975). Although this is often
2 referred to in Washington as "the voluntary rescue doctrine," the principle is broader: "In certain
3 circumstances, a person may be liable in negligence if he or she gratuitously assumes a duty to act
4 on behalf of another and fails to act with due care in performing that duty." *Meneely v. S.R.*
5 *Smith, Inc.*, 101 Wn.App. 845, 856, 5 P.3d 49, 55 (2000).

6 In *Meneely*, the court determined that a trade association, which undertook to establish
7 safety standards for swimming pools and diving boards, could be held liable for doing so
8 negligently.⁵⁰²

9 By promulgating industry wide safety standards that pool and board manufacturers
10 relied upon, NSPI voluntarily assumed the duty to warn Mr. Meneely and other
11 divers of the risk posed by this type of board on a Type II pool. It failed to exercise
12 reasonable care in performing that duty, when it did not change the standard after it
13 knew that studies showed the pool and board combination was dangerous for
14 certain divers.

15 101 Wn. App. at 859-60, 5 P.3d at 57.

16 Similarly, in *Sheridan v. Aetna Cas. & Sur. Co.*, 3 Wn.2d 423, 439, 100 P.2d 1024 (1940),
17 the Washington Supreme Court held that an insurance company, which had agreed under the
18 terms of its policy with a building owner to inspect the building's elevator and file required
19 reports, was liable to a third person injured when the elevator malfunctioned, for inspecting
20 negligently.⁵⁰³

21 ⁵⁰² Notably, the *Meneely* court did not feel it necessary to wrestle with any question about
22 whether such a claim would be preempted by the WPLA.

23 ⁵⁰³ A similar rule is stated in Restatement (Second) of Torts, § 324A, which provides,

One who undertakes, gratuitously or for consideration, to render services to another
which he should recognize as necessary for the protection of a third person or his
things, is subject to liability to the third person for physical harm resulting from his
failure to exercise reasonable care to protect his undertaking, if

(a) his failure to exercise reasonable care increases the risk of such harm, or

1 Thus, although a manufacturer would not have any duty to train buyers how to use its
2 product (beyond providing adequate instructions and warnings) simply because it built the
3 product, if it undertakes to provide such training, it is liable if it does so negligently. This is true
4 in the same way that a non-manufacturer, who undertook to provide training in the use of
5 someone else's product, would be liable for doing so negligently.

6 If a party raises a question of fact regarding whether a defendant has assumed and
7 breached a duty of care, the issue must go to the jury. *See Alston v. Blythe*, 88 Wn.App. 26, 37,
8 943 P.2d 692, 698 (1997) (holding that plaintiff had raised a fact question as to whether a truck
9 driver had assumed a duty to help her safely cross the road by testifying that the driver, who was
10 stopped in the line closest to her, had waved her to cross); *Panitz v. Orange*, 10 Wn.App. 317,
11 319-21, 518 P.2d 726, 728-29 (1973) (finding jury question under facts very similar to *Alston*).

12 **2. There is Substantial Evidence that ISI Undertook to Train Doctors,
13 Including Dr. Bildsten, to Use its Robot in Surgeries.**

14 The evidence discussed above establishes that ISI undertook to train doctors not just in
15 how its machine worked, but in how to use that machine to perform operations. ISI created
16 "clinical pathways" for its trainees, dictating a path from no robotic experience to performing
17 surgeries without supervision on patients in a few short steps. "The Clinical Pathway and
18 Training Protocol" was a "Prostatectomy" pathway and training protocol.⁵⁰⁴ It stated it had been
19 "put in place to ensure success in becoming a proficient robotic surgeon." ISI represents that the

20 (b) he has undertaken to perform a duty owed by the other to the third person, or

21 (c) the harm is suffered because of reliance of the other or the third person upon the
undertaking.

22 Washington has not yet adopted Section 324A. *See Meneely*, 101 Wn.App. at 862 n.4 (noting
23 that because Washington law supported trial court's finding that a duty existed, it did not have
to consider Section 324A.

⁵⁰⁴ PT-42, Exhibit A, at 1.

1 pathway was developed from “the best practices around the country.”⁵⁰⁵ ISI specifically promised

2 Harrison Hospital:

3 Intuitive Surgical training programs are designed to provide surgeons with the
4 knowledge and skills necessary to utilize the da Vinci® S™ Surgical System for its
intended use in a variety of endoscopic surgical procedures.^[506]

5 The Clinical Pathway itself focused on ISI’s scaled-back training phases, including the
6 off-site training at ISI’s Porcine Lab. That training, however, had to be immediately followed by
7 2 proctored surgeries:

8 6. Off Site Training – Porcine Lab, 1-2 days.

- 9 • Live Skills Lab at ISI training center – 2 Cases must be booked before departure
10 for lab to ensure early success. Training will be cancelled if cases are not booked.
Training fee \$3,000.^[507]

11 Given that surgeries need to be scheduled even before the training was received, and needed to be
12 performed soon after the doctor returned from the training, ISI must have realized that the training
13 it provided would be viewed as fully preparing surgeons to perform those procedures. In fact, ISI
14 told its CSRs: “*All necessary training for surgeons and nurses is built into the Clinical*
15 *Plan.*”⁵⁰⁸

16 ISI further represented to Harrison that it had expertise in starting a robotic practice and
17 that its clinical pathway was the key to success. In April 2008, ISI made a presentation to
18 Harrison. On a page titled, “Highlights of Best Practices,” ISI stated,

19 Consultant analyzed 20 robust robotic surgery programs to determine “Best
20 Practices”. Essential activities include:

21 * * *

- Partnership with Intuitive Surgical – experience from 600 other launches

22 ⁵⁰⁵ PT-42, Exhibit A, at 1.

23 ⁵⁰⁶ PT-108, at ISI30611.

⁵⁰⁷ PT-42, Exhibit A, at 1.

⁵⁰⁸ PT-30, at ISI10878 (emphasis added).

- 1 • Follow Intuitive’s *prescribed training pathway* – surgeons and staff⁵⁰⁹

2 In fact, ISI has openly marketed its central role in surgical training. In one of its
3 brochures, ISI summarizes its role in a hospital’s da Vinci surgery program.

4 Intuitive Surgical would like to be an integral part of your *da Vinci* Surgery
5 program. We can:

- 6 □ **Take the lead in coordinating *da Vinci* System installation, on-site
7 training, staff in-servicing and surgeon training**

8 * * *

- 9 □ **Work with surgeons to develop and execute their clinical paths**
10 □ Coordinate site visits, case observations and proctors
11 □ **Actively support cases in the OR;** support surgeon as well as staff;
12 provide verbal technical assistance in the safe and effective use of the *da*
13 *Vinci* Surgical System
14 □ **Actively work with surgeons to help advance *da Vinci* surgical skills –**
15 e.g. scheduling inanimate labs to develop technical skills⁵¹⁰

16 ISI must have also known that Harrison, like other hospitals, was following its lead with
17 respect to the amount of training required before surgeons like Dr. Bildsten could perform robotic
18 surgery without supervision. Harrison’s da Vinci Steering Committee relied on information from
19 ISI’s representatives, including “samples of credentialing criteria.”⁵¹¹ Shortly after receiving
20 these samples and ISI’s *Clinical Pathway*, the Committee started considering and eventually
21 adopted draft Credentialing Criteria which mirrored ISI’s *Clinical Pathway*. Under the adopted
22 criteria, Dr. Bildsten could not perform robotic surgery at Harrison until he “documented
23 successful completion of the hands-on training ... required by the manufacturer.”⁵¹² Three ISI
representatives – Dave Carson, Sean O’Connor, and Damon Daniels – attended the Committee

509 PT-1, at IS1026 (emphasis added)

510 PT-72, at 8.

511 PT-82.

512 Exhibit Q to Mullenix Declaration (Bildsten deposition) at 53:25-54:8.

1 meetings, so ISI must be charged with knowledge that Harrison was relying on the training it
2 provided.

3 In this regard, ISI argues that it cannot be held liable for Harrison's credentialing
4 decisions, such as its decision to allow Dr. Bildsten (and other doctors) to perform unsupervised
5 robotic surgeries after they had only received ISI's limited training and had two proctored
6 surgeries. But Mrs. Taylor does not seek to hold ISI responsible for Harrison's actions, only its
7 own. ISI's discussion of this point somehow manages to overlook the fact that the Harrison
8 committee that investigated possible credentialing standards received all of its information from
9 ISI, which had promised to partner with Harrison in developing standards.⁵¹³ As they were taught
10 to do in their ISI training, ISI's salespeople sat with the committee and provided "expertise" on
11 what other hospitals were doing, with an eye toward preventing hospitals from adopting
12 "credentialing guidelines ... that might be challenging in starting their program" (that is, difficult
13 for doctors to satisfy quickly).⁵¹⁴ Because ISI undertook to provide expertise to Harrison
14 regarding credentialing, it can be liable if it did so unreasonably, regardless of whether Harrison
15 can be blamed for following its advice.

16 Even more importantly, there is no dispute that ISI knew Harrison decided to adopt the
17 standards ISI recommended, allowing a doctor to be credentialed after completing the
18 manufacturer's training and two proctored surgeries. As a result, ISI was aware that Harrison and
19 Dr. Bildsten were relying upon ISI's training – and nothing else – to equip Dr. Bildsten to safely
20 perform operations without supervision after only two proctored surgeries. ISI also knew that it
21

22 ⁵¹³ Exhibit A to Mullenix Declaration (Daniels Deposition) at 225:13-16 ("Q. ... [A]re you
23 aware of anything that Harrison had as they're making their credentialing decision that wasn't
provided by ISI? A. No. I'm not aware of it.").

⁵¹⁴ PT-137.

1 would take at least 50 robotic procedures before a new robotic surgeon would be sufficiently
2 competent to perform robotic surgery safely on a patient like Fred Taylor.⁵¹⁵ Yet ISI never told
3 Dr. Bildsten or Harrison that the training it provided was not adequate. By withholding this
4 information in this context, ISI further confirmed that it was undertaking to train Dr. Bildsten.

5 ISI also commissioned step-by-step procedure guides describing specific surgical
6 procedures to be done with the da Vinci robot. It handed out those procedure guides to surgeons
7 seeking training for those procedures. It told hospitals, including Harrison, that doctors needed to
8 “learn” its guides as “part of training” for robotic surgery.⁵¹⁶

9 ISI also provided its training separately from the sale of its machines, further
10 demonstrating that the training was not just a part of the sale of the robot. As the sales contract
11 between ISI and Harrison demonstrates, hospitals or doctors could pay for training separate from
12 the purchase price.⁵¹⁷ At the time, the price was \$3,000 per doctor.⁵¹⁸ And although Dr. Bildsten
13 received his training through one of the training slots provided for no additional cost with the
14 purchase, his training was no different from the training provided others.

15 ISI may claim that it cannot be liable for negligent training because in addition to the
16 statements and conduct set forth above, it also often made fine print disclaimers of its ability to
17 train “on procedures.” For example, the same document that tells surgeons to “[l]earn the
18 procedure guide”⁵¹⁹ as “part of training”⁵²⁰ also states, in fine print, and on the last page:
19 “Intuitive Surgical does not provide clinical training ... or train in surgical procedures or
20

21 ⁵¹⁵ Helton Declaration at ¶15.

22 ⁵¹⁶ PT-73 at 6.

23 ⁵¹⁷ PT-110 at 30627.

⁵¹⁸ *Id.*

⁵¹⁹ PT-73 at 6.

⁵²⁰ PT-73 at 6.

1 techniques.”⁵²¹ Likewise, ISI’s website at the time of the sale to Harrison described “Procedure
2 Training” as one of “three components” of ISI’s “comprehensive training pathway.”⁵²² On the
3 same page, ISI contradicted itself, stating: “Intuitive Surgical is in no way responsible ... for
4 training in surgical procedure or technique[.]”

5 Pasting disclaimers at the end of documents to negate responsibility for things you have
6 done in those documents might provide some defense if the plaintiff in this case were Dr.
7 Bildsten or Harrison. But ISI’s behavior also negligently endangered an entire class of foreseeable
8 victims: the patients of surgeons who did not know they had received inadequate training.

9 Disclaimer or no, ISI convinced every relevant decision maker that its Clinical Pathway,
10 including the training in Sunnyvale, was sufficient to get surgeons ready to perform unsupervised
11 procedures on live humans. To CSRs, ISI made clear that its training was for use of the robot
12 “in clinical applications,”⁵²³ or “procedural applications,”⁵²⁴ and was “[a]ll necessary
13 training.”⁵²⁵ ISI told hospitals that it had a “*Comprehensive* Clinical Training Continuum”⁵²⁶
14 and that it would measure surgeons’ progress “against state-of-the-art technique.”⁵²⁷ It
15 specifically told Harrison that its programs were “designed to provide surgeons with the
16 knowledge and skills necessary to utilize the da Vinci S Surgical System for *its intended use in*

17
18
19 ⁵²¹ PT-72 at 8.

20 ⁵²² May 13, 2008, version portion of ISI website devoted to explaining training program to
hospitals; Mullenix Declaration at ¶ 6.

21 ⁵²³ PT 212 (emphasis added); Exhibit A to Mullenix Declaration (Daniels Deposition) at
258:10-22; 211:17-18 (“I told [surgeons] ... here’s our clinical pathway document, you know,
you should abide by this”).

22 ⁵²⁴ Exhibit A to Mullenix Declaration (Daniels Deposition) at 266:1-8.

23 ⁵²⁵ PT-30 at 10878; Exhibit B to Mullenix Declaration (Nagel Deposition) at 59:10-11.

⁵²⁶ PT-104 at 259 (emphasis added).

⁵²⁷ PT-72 at 6.

1 *a variety of endoscopic surgical procedures.*⁵²⁸ And as noted, ISI told doctors to “[l]earn the
2 procedure guide”⁵²⁹ as “part of training.”

3 ISI wants to be let off the hook for its inadequate training program because it, sometimes,
4 spoke out of both sides of its mouth: stating that its training was in procedures and would ensure
5 safety, followed by a disclaimer that it could not train in procedures nor ensure safety. A jury
6 should decide whether those disclaimers allow ISI to avoid responsibility for its training program,
7 *i.e.*, whether ISI *undertook* to train in procedures in spite of its disclaimers. It should be noted that
8 many of ISI’s documents did *not* contain these disclaimers. Most importantly, the Clinical
9 Pathway document was disclaimer free.⁵³⁰ In fact, Damon Daniels admitted that he would tell the
10 surgeons, and wanted those surgeons to believe, that the clinical pathway would ensure the
11 surgeon’s success in becoming a proficient robotic surgeon.⁵³¹

12 For all of these reasons, there is clearly a factual question regarding whether ISI undertook
13 to provide training to Dr. Bildsten on how to use the robot in surgery. Therefore, the jury must
14 answer this question. If the jury determines that ISI’s assumed duties beyond the mere instruction
15 and labeling of a product, product liability law does not apply, and the jury will have to determine
16 whether ISI breached the duty it undertook.

17 **3. There is Substantial Evidence that ISI Negligently Trained Dr.
18 Bildsten**

19 Because ISI undertook to provide training to Dr. Bildsten, it had a duty to provide
20 reasonable training. Mrs. Taylor is prepared to show that ISI’s training was not sufficient to make
21

22 ⁵²⁸ PT-108 at 30611 (emphasis added).

23 ⁵²⁹ PT-73 at 6.

⁵³⁰ PT-42.

⁵³¹ Exhibit A to Mullenix Declaration (Daniels Deposition) at 268:22-269:5.

1 doctors competent to perform robotic surgery and that ISI withheld this information from doctors
2 and hospitals while encouraging them to practice on patients.

3 As explained fully in Section II(G) above, the training actually provided to Dr. Bildsten
4 was deficient in many ways. At the outset, ISI's trainers were not "expert" in any way: neither
5 the Sunnyvale trainer nor Damon Daniels had any prior medical or educational expertise.⁵³²
6 Moreover, as Dr. Helton has opined, the training program implemented as a whole "lacks depth
7 and breadth, is incomplete, and is potentially unsafe."⁵³³ Specifically, the program was not
8 "comprehensive," was not marked by "consistent" assessments, was not conducted by
9 "experts," and was not conducted using developed "metrics."⁵³⁴ Rather, the assessments that
10 were conducted were either not tests at all (such as the ten question online quiz for Phase One
11 on which it was impossible to provide a wrong answer), or they were part of a protocol (Phase
12 Two training in Sunnyvale) that, outside extraordinary exceptions, has never been failed. There
13 was at no point the promised training on insufflator settings,⁵³⁵ and surgeons were never
14 required to perform the specific surgical skills for a given surgery.⁵³⁶ Dr. Bildsten certainly
15 never removed a prostate in Sunnyvale: pigs do not have prostates.⁵³⁷ Surgeons did not even
16 self-assess on specific skills, let alone their ability to perform specific procedures.⁵³⁸ Phase
17

18 _____
⁵³² Helton Declaration at ¶5.

19 ⁵³³ Helton Declaration at ¶7.

20 ⁵³⁴ Exhibit H to Mullenix Declaration (Lederer Deposition) at 77:24-78:2.

21 ⁵³⁵ PT-10 at 27609; Exhibit B to Mullenix Declaration (Nagel Deposition) at 47:14-15.

22 ⁵³⁶ Exhibit H to Mullenix Declaration (Lederer Deposition) at 45:5-10 ("As it relates to urology
is nonspecific."); Exhibit G to Mullenix Declaration (Curet Deposition) at 63:16-19 ("Q. As I
am understanding what you're saying, you're saying ISI does not train on how to do procedures,
including robotic prostatectomy. A. That's correct."); at 76:14-15 ("We aren't in the position to
teach somebody how to do a procedure.").

23 ⁵³⁷ PT-243 (Lieberman Article Excerpt) at 18 ("pigs have no fat or prostate gland").

⁵³⁸ Exhibit B to Mullenix Declaration (Nagel Deposition) at 79:21-23, 81:8-18.

1 Three did not require practice of procedures on cadavers;⁵³⁹ it consisted solely of a dry run
2 without an anesthesiologist.⁵⁴⁰ At most, the surgeon might come in on his or her off-time to
3 practice, though Damon Daniels cannot remember if Dr. Bildsten was actually required to even
4 do that.⁵⁴¹ Dr. Bildsten was offered nothing with respect to Phase Four before actually
5 performing (proctored) procedures on live humans.⁵⁴² ISI did not train Dr. Bildsten in the
6 dangers of excessive blood loss, the dangers of extremely long surgeries, proper insufflation
7 techniques, or the need for a watertight anastomosis after violating the peritoneum with robotic
8 arms.⁵⁴³ Patient positioning was discussed only insofar as surgeons (many of whom, like
9 Bildsten, had no laparoscopic experience) were told "that it should be similar to what they
10 would be doing laparoscopically."⁵⁴⁴ ISI does not train surgeons on patient selection.⁵⁴⁵ And
11 perhaps most importantly, it does not provide them with realistic expectations about the truly
12 steep learning curve for robotic surgery.⁵⁴⁶ Rather, ISI discusses the learning curve as though
13 the only issue were surgeon comfort, not patient safety and oncological outcome.⁵⁴⁷ At trial, the
14 testimony of Dr. Bildsten, Dr. Ramin, Dr. Lohrasbi, and Dr. Helton will show the danger that
15
16

17 ⁵³⁹ See Exhibit I to Mullenix Declaration (O'Connor Deposition) at 53:23-54:9, 54:11-12.

18 ⁵⁴⁰ Exhibit I to Mullenix Declaration (O'Connor Deposition) at 54:11-12 (training between
19 offsite training and first cases consists of 45 minute dry run the night before the first case);
20 Exhibit B to Mullenix Declaration (Nagel Deposition) at 74:4-5.

21 ⁵⁴¹ Exhibit A to Mullenix Declaration (Daniels Deposition) at 180:20-181:7.

22 ⁵⁴² Exhibit A to Mullenix Declaration (Daniels Deposition) at 250:3-25.

23 ⁵⁴³ Exhibit H to Mullenix Declaration (Lederer Deposition) at 54:8-13 (blood loss); Exhibit B to
Mullenix Declaration (Nagel Deposition) at 47:5-10 (long surgeries); Bildsten Declaration, at ¶
9 (insufflation and anastomosis).

⁵⁴⁴ Exhibit H to Mullenix Declaration (Lederer Deposition) at 103:21-23.

⁵⁴⁵ Exhibit B to Mullenix Declaration (Nagel Deposition) at 42:14-25.

⁵⁴⁶ Helton Declaration at ¶15.

⁵⁴⁷ Helton Declaration at ¶¶16-17.

1 training of this nature can pose, particularly with a difficult surgical candidate like Fred Taylor.
2 In Dr. Helton's words, ISI was "irresponsible and reckless."⁵⁴⁸

3 **4. Conclusion**

4 There are genuine factual disputes as to whether ISI undertook to provide training to
5 doctor Bildsten on how to use the robot in surgery, and as to whether it did so negligently.
6 Accordingly, ISI's motion for summary judgment on Mrs. Taylor's negligence claim should be
7 denied.

8 **E. There is a Genuine Factual Dispute as to Whether, Under the WPLA, the**
9 **Warnings Given by ISI Were Inadequate and Negligent.**

10 The WPLA provides that a manufacturer is liable for providing inadequate warnings or
11 instructions:

12 (1) A product manufacturer is subject to liability to a claimant if the claimant's
13 harm was proximately caused by the negligence of the manufacturer in that the
14 product was not reasonably safe as designed or not reasonably safe because
15 adequate warnings or instructions were not provided.

16 ...
17 (b) A product is not reasonably safe because adequate warnings or instructions
18 were not provided with the product, if, at the time of manufacture, the likelihood
19 that the product would cause the claimant's harm or similar harms, and the
20 seriousness of those harms, rendered the warnings or instructions of the
21 manufacturer inadequate and the manufacturer could have provided the warnings or
22 instructions which the claimant alleges would have been adequate.

23 (c) A product is not reasonably safe because adequate warnings or instructions
were not provided after the product was manufactured where a manufacturer
learned or where a reasonably prudent manufacturer should have learned about a
danger connected with the product after it was manufactured. In such a case, the
manufacturer is under a duty to act with regard to issuing warnings or instructions
concerning the danger in the manner that a reasonably prudent manufacturer would
act in the same or similar circumstances. This duty is satisfied if the manufacturer
exercises reasonable care to inform product users.

⁵⁴⁸ Helton Declaration at ¶¶20.
PLAINTIFF'S OPPOSITION TO ISI MOTION FOR
SUMMARY JUDGEMENT ON ALL CLAIMS

1 RCW 7.72.030(1). In this case, because ISI's robotic surgical system is a medical device that can
2 be legally used on patients only by licensed physicians, ISI's duty is to provide adequate warnings
3 and instructions to Dr. Bildsten. See *Terhune v. A.H. Robins Co.*, 90 Wn.2d 9, 13, 577 P.2d 975,
4 977 (1978) (adopting the "learned intermediary" doctrine, under which "the duty of the
5 manufacturer to warn of dangers involved in use of a product is satisfied if he gives adequate
6 warning to the physician who prescribes it").

7 ISI also claims that because this case involves a medical product, all product claims are
8 also subject to Restatement (Second) of Torts § 402A, comment k.⁵⁴⁹ This is incorrect. Comment
9 k addresses the fact that certain products, such as prescription drugs and medical products, cannot
10 be made entirely safe for their intended use. It addresses defective design, not failure to warn.
11 Pursuant to comment k, "[s]uch a product, properly prepared, **and accompanied by proper**
12 **directions and warnings**, is not defective, nor is it unreasonably dangerous." *Id.* (emphasis
13 added). "The seller of such products, **again with the qualification that** they are properly prepared
14 and marketed, and **proper warning is given**, where the situation calls for it, is not to be held to
15 strict liability for unfortunate consequences attending their use" *Id.* (emphasis added). As the
16 Washington Supreme Court recognized in *Terhune*, "The comment does not purport to state what
17 is 'proper warning' where such a product is involved." 90 Wn.2d at 13, 577 P.2d at 977. As
18 comment k does not address when a warning or instruction is adequate and Mrs. Taylor's only
19 remaining product claim is for improper warnings and instructions, comment k simply plays no
20 role in resolving the issues in this case.⁵⁵⁰

21
22 ⁵⁴⁹ The Washington Supreme Court adopted comment k in *Terhune*, 90 Wn.2d at 12-13, 577
P.2d at 977.

23 ⁵⁵⁰ In *Young v. Key Pharmaceuticals, Inc.* ("Young IP"), 130 Wn.2d 160, 922 P.2d 59 (1996),
the Washington Supreme Court, in a case arising before the adoption of the WPLA, divided
PLAINTIFF'S OPPOSITION TO ISI MOTION FOR
SUMMARY JUDGEMENT ON ALL CLAIMS

1 Since the adoption of the WPLA in 1981, the standard for establishing a failure to warn
2 claim is set forth in the Act, at RCW 7.72.030(1) (b & c). As quoted above, a manufacturer is
3 liable if the product it supplies is “not reasonably safe because adequate warnings or instructions
4 are not provided” or if the manufacturer should have learned of dangers of the product later, but
5 fails to provide additional warnings reasonably necessary.

6 In order to determine if the warnings and instructions provided with the product are
7 adequate, the jury must determine, “if, at the time of manufacture, the likelihood that the product
8 would cause the claimant's harm or similar harms, and the seriousness of those harms, rendered
9 the warnings or instructions of the manufacturer inadequate and the manufacturer could have
10 provided the warnings or instructions which the claimant alleges would have been adequate.”
11 RCW 7.72.030(1)(b); *see also* WPI 110.03 (failure to warn instruction containing similar
12 language).

13 There is substantial evidence the risks associated with the use of ISI’s robotic system by
14 those without sufficient experience or training were great, and rendered the instructions and
15 warnings provided by ISI inadequate.

16 **1. There is a Question of Fact About Whether ISI’s Instructions or**
17 **Warnings Were Inadequate**

18 Whether or not instructions and warnings are adequate is an inherently factual question.
19 *See Estate of LaMontagne v. Bristol-Myers Squibb*, 127 Wn. App. 335, 343, 111 P.3d 857, 861
20 (2005) (“Generally, the adequacy of a warning will be a question of fact.”), citing *Little v. PPG*

21 equally over the question of whether a common law failure to warn claim arising from a
22 defective drug should be subject to a negligence standard or a failure to warn standard.
23 *Compare* 130 Wn.2d at 168-69 (stating the negligence standard should apply) with 130 Wn.2d
at 179-88 (stating that comment k does not apply to failure to warn claims, and strict liability
should continue to apply). As discussed in the main body of this opposition, this decision is no
longer relevant because RCW 7.72.030, not the common law, now governs failure to warn
claims.

PLAINTIFF’S OPPOSITION TO ISI MOTION FOR
SUMMARY JUDGEMENT ON ALL CLAIMS

FRIEDMAN | RUBIN
1126 HIGHLAND AVE.
BREMERTON, WA 98312
PHONE (360) 782-4300
FACSIMILE (360) 782-4358

1 *Inclus., Inc.*, 92 Wash.2d 118, 123, 594 P.2d 911 (1979), and *Haysom v. Coleman Lantern Co.*, 89
2 Wn.2d 474, 573 P.2d 785 (1978). Such questions can be resolved on summary judgment only if
3 “reasonable minds can reach only one conclusion from the admissible evidence.” *Estate of*
4 *LaMontagne*, 127 Wn. App. at 343, 111 P.3d at 861, citing *Smith v. Safeco Ins. Co.*, 150 Wn.2d
5 478, 485, 78 P.3d 1274 (2003). This is not such a case.

6 As Dr. Bildsten makes clear in his declaration, he was not warned that the training
7 program was not FDA approved (and was given the contrary impression).⁵⁵¹ He was not warned
8 the ISI training program *did not* prepare him to operate on live patients.⁵⁵² He was not warned
9 that with no prior laproscopic experience, it was very unlikely he could achieve results
10 comparable to his traditional approach for his patients until he had completed 100 or more robotic
11 surgeries.⁵⁵³ As Dr. Helton’s declaration makes clear, these deficiencies in the warning Dr.
12 Bildsten received were “irresponsible and reckless.”⁵⁵⁴

13 Moreover, Dr. Bildsten was not warned of the need to ensure a watertight urethral
14 anastomosis or of the dangers of insufflating patients during long surgeries at levels over 15
15 millimeters of mercury.⁵⁵⁵ He was not warned that da Vinci Prostatectomy should be performed
16 only in steepest Trendelenburg.⁵⁵⁶

17 As Dr. Bildsten further explains in his declaration, contrary to ISI’s argument, Dr. Bildsten
18 did not consider the information that was withheld from him obvious, and if he had been
19 conveyed full information, it would altered his conduct, causing him to either not perform da
20

21 ⁵⁵¹ Bildsten Declaration at ¶3.

22 ⁵⁵² Bildsten Declaration at ¶4.

23 ⁵⁵³ Bildsten Declaration at ¶8.

⁵⁵⁴ Helton Declaration at ¶20.

⁵⁵⁵ Bildsten Declaration at ¶9.

⁵⁵⁶ PT-266 (ISI’s Answers to Plaintiff’s Second Requests for Production) at RFP 51.

1 Vinci surgery on Mr. Taylor, or perform it in a different manner to reduce the risk of harm to Mr.
2 Taylor.⁵⁵⁷

3 The jury may not agree with Drs. Bildsten and Helton, but there is no basis to find against
4 their testimony as a matter of law.

5 **2. ISI Could Have Provided Adequate Instructions and Warnings**

6 The second requirement for establishing a failure to provide an adequate instruction or
7 warning claim under RCW 7.72.030(1)(b) is showing “the manufacturer could have provided the
8 warnings or instructions which the claimant alleges would have been adequate.” This is easily
9 satisfied. ISI could very easily have provided proper warnings and instructions. For example,
10 ISI’s early training program, at least as proposed to the FDA, would likely have provided
11 adequate instructions.

12 Moreover, in light of ISI’s knowledge about the learning curve for da Vinci surgeries, ISI
13 could easily have warned doctors, in these or similar words,

14 **It takes experience with 20 patients or more to achieve basic competency in the**
15 **use of the da Vinci surgical system. Physicians should operate only under the**
16 **supervision of a more experienced da Vinci surgeon until that point. It is**
17 **strongly recommended that doctors not attempt to use the da Vinci system to**
operate on high risk patients, such as those who are obese, have major or
multiple prior abdominal surgeries, or have diabetes or heart conditions, until
more than 50 da Vinci surgeries have been performed.

18 It made no such effort.

19 **F. ISI’s Negligent Training and Inadequate Instructions and Warnings are a**
20 **Proximate Cause of Mr. Taylor’s Injuries and Her Damages**

21 In its motion, ISI argues in two different sections that Mrs. Taylor cannot establish that its
22 conduct was a proximate cause of Mr. Taylor’s injuries. To make these arguments, ISI is forced
23 to misrepresent Mr. Taylor’s injuries and the nature of her claims. Properly understood, there is

⁵⁵⁷ Bildsten Declaration at ¶¶6-9.
PLAINTIFF’S OPPOSITION TO ISI MOTION FOR
SUMMARY JUDGEMENT ON ALL CLAIMS

1 ample evidence that ISI's breaches of its duty of care and its inadequate instructions and warnings
2 caused Mr. Taylor's injuries and the resulting losses to his family.

3 "Issues of negligence and proximate cause are generally not susceptible to summary
4 judgment." *Owen v. Burlington Northern & Santa Fe R.R. Co.*, 153 Wn.2d 780, 788, 108 P.3d
5 1220, 1223 (2005), quoting *Ruff v. King County*, 125 Wn.2d 697, 703, 887 P.2d 886 (1995)
6 (additional citations omitted); see also *Hertog, ex. rel. S.A.H. v. City of Seattle*, 138 Wn.2d 265,
7 275, 979 P.2d 400, 406 (1999) ("Breach and proximate cause are generally fact questions for the
8 trier of fact.").

9 [I]n cases involving alleged medical negligence,⁵⁵⁸ if a reasonable person could
10 infer, from the facts, circumstances, and medical testimony, that a causal
11 connection exists, the evidence is sufficient to survive summary judgment. The
12 plaintiff need not establish causation by direct and positive evidence, but only by a
13 chain of circumstances from which the ultimate fact required is reasonably and
14 naturally inferable.

15 *Attwood v. Albertson's Food Centers, Inc.*, 92 Wn. App. 326, 330-31, 966 P.2d 351, 353 (1998),
16 citing *Douglas v. Freeman*, 117 Wn.2d 242, 252, 814 P.2d 1160 (1991); *McLaughlin v. Cooke*,
17 112 Wash.2d 829, 837, 774 P.2d 1171 (1989); and *Teig v. St. John's Hosp.*, 63 Wn.2d 369, 381,
18 387 P.2d 527 (1963).

19 ISI argues that any failure to warn cannot have caused any harm because Dr. Bildsten
20 admitted being told that he should choose patients with a relatively low BMI and relatively simple
21 cases. But Dr. Bildsten had never had a complication in over 100 prostatectomies.⁵⁵⁹ From this
22 the jury can infer he was a competent, careful, conscientious surgeon. ISI undertook to train him
23 in a new technique. After doing all the training they asked him to do, Dr. Bildsten then made a
series of mistakes. Some of the mistakes had nothing to do with Mr. Taylor's weight—like failure

⁵⁵⁸ The cause of action against ISI is not for medical negligence, but obviously, this case does
involve injuries suffered in a medical procedure.

⁵⁵⁹ Bildsten Declaration at ¶7.

1 to attempt a water-tight anastomosis and creating too great insufflation pressure. Admittedly, ISI
2 never trained or warned on these issues and, as outlined above, there is evidence from which a
3 jury could conclude these mistakes caused injury to Mr. Taylor.

4 ISI gave Dr. Bildsten a Clinical Pathway he could not possibly follow. He was set up to
5 either fail in his “commitment” to do “one case per week” or in his commitment to only do simple
6 patients for his early cases.⁵⁶⁰ A jury could find that the Clinical Pathway document itself was
7 negligently constructed and invited failure.

8 Additionally, the jury could agree with Drs. Bildsten and Helton that simply telling Dr.
9 Bildsten to refrain from operating on patients with high BMI was not an adequate warning. In
10 fact, Damon Daniels would tell surgeons that the longer they waited between procedures, the
11 more their skills would degrade.⁵⁶¹ They could agree with Dr. Bildsten that if he had been given
12 adequate warnings, things would have been very different: “there may have been no
13 complications, and injury to Fred E. Taylor, if any, *would have been significantly less.*”⁵⁶² There
14 is no basis to say otherwise as a matter of law.

15 ISI also states, “Dr. Bildsten testified at the time of the September 9, 2008 prostatectomy
16 he felt well trained to use the da Vinci system.” This does not, as ISI implies, establish that he
17 *was* well trained, just that he thought so at the time. As shown above, Dr. Bildsten now believes
18 that he was not adequately prepared and that if told additional information by ISI, he would have
19 acted differently. Mr. Taylor was injured in this case *because* ISI convinced Dr. Bildsten that he
20 would be ready to perform robotic surgeries after a brief training and two proctored surgeries and
21 Dr. Bildsten proceeded with understandable, but misguided confidence.

22 _____
⁵⁶⁰ PT-42 at 42.

23 ⁵⁶¹ Exhibit A to Mullenix Declaration (Daniels Deposition) at 292:7-10.

⁵⁶² Bildsten Declaration, at ¶ 7 (emphasis added)

1 In Section V.H. of its motion, ISI argues that Mrs. Taylor cannot establish any causal
2 connection between its acts and the injuries involved in this case. This entire argument is based
3 on two false premises: 1) that the only injury Mr. Taylor suffered was a rectal tear; and 2) that it
4 is undisputed that the rectal tear occurred after Dr. Bildsten converted the Taylor surgery from
5 robotic to open surgery.

6 As discussed above, Mr. Taylor suffered a number of harms in this surgery, including
7 extreme loss of blood, hypovolemic shock, an extended period of time under anesthesia, acute
8 renal failure (kidney failure), encephalopathy (impaired brain function), acute rhabdomyolysis
9 (break down in muscle tissue), critical illness myopathy (muscle disease), urethral anastomotic
10 leak (non-watertight urethra), femoral nerve injury, stroke, acute respiratory failure, metabolic
11 acidosis (abnormally acidic body fluids), severe urethral contracture (shortened urethra), pleural
12 effusions (fluid on the lungs), and permanent incontinence, all in addition to the rectal tear.⁵⁶³
13 None of these injuries were solely caused by the rectal tear,⁵⁶⁴ and many were directly related to
14 the length of the surgery and Dr. Bildsten's difficulty in visualization within Mr. Taylor.⁵⁶⁵

15 Even if the rectal tear were the only injury, it is a disputed question of fact as to when it
16 occurred. While Dr. Bildsten did assert in his deposition that he believed the tear did not occur
17 until after he converted to an open procedure, and was caused by his finger, this is contradicted by
18 the testimony of the surgeon who repaired the tear, Dr. Fleischhauer, and robotic urology expert
19 Dr. Adam Ramin. Dr. Fleischhauer testified that the tear "looked clean," not "ragged" and that it

20
21 _____
⁵⁶³ PT-248 (ISI's Response to Plaintiffs' First Requests for Admission) at RFA 9-13, 16-18, 20-
22 21, 24-26.

⁵⁶⁴ PT-248 (ISI's Response to Plaintiffs' First Requests for Admission) at RFA 9-13, 16-18, 20-
23 21, 24-26.

⁵⁶⁵ Swerdlow Declaration at ¶¶

1 looked like "it was a surgical instrument ... that made the laceration."⁵⁶⁶ Dr. Ramin testified at
2 his deposition that, in his opinion, the tear occurred during the da Vinci procedure, as Dr.
3 Bildsten's reported difficulty visualizing in an area extremely close to the rectum, where there
4 is "a high risk of cutting into the rectum and not realizing it."⁵⁶⁷

5 Proximate cause is an issue for the jury here, just as it is in most cases.

6 **G. It Is Irrelevant that ISI and Its Clinical Sales Representatives Are Not Health**
7 **Care Providers**

8 ISI argues extensively that neither it nor its clinical sales representatives are medical
9 providers within the meaning of RCW 7.70.020. Mrs. Taylor never claimed otherwise. The
10 services ISI performed or purported to perform were not health care. Chapter 7.70, Actions for
11 Injuries Resulting From Health Care, is not at issue in this dispute between Mrs. Taylor and ISI.
12 It does not follow, however, that ISI gets a free pass for its negligence and the negligence of its
13 employees.

14 Nor is ISI's negligence analogous to that of the pharmacist in *McKee v. American Home*
15 *Products*, 113 Wn.2d 701, 782 P.2d 1045 (1989), on which ISI relies. ISI is not being sued for
16 not second-guessing Dr. Bildsten; it is being sued for not training him properly and not providing
17 him with information he needed to know to exercise his proper medical judgment. Mrs. Taylor
18 does assert that, because ISI assumed the duty to train Dr. Bildsten and undertook to "partner"
19 with him in the implementation of a robotic surgery practice, its responsibility to properly inform
20 Dr. Bildsten continued into the operating room. But this is neither the heart of the cause of the
21 action nor an intrusion into the doctor patient relationship. If ISI had trained Dr. Bildsten
22 properly, he would have known everything he needed to know to treat Mr. Taylor safely before

23 ⁵⁶⁶ Exhibit T to Mullenix Declaration (Fleischhauer Deposition) at 59:4-19.

⁵⁶⁷ Exhibit D to Mullenix Declaration (Ramin Deposition) at 79:10-80:3.

1 the operation started. ISI's presence in the operating room, in the person of Damon Daniels,
2 simply gave ISI one last chance to correct its prior errors. If ISI had done so, it would not have
3 intruded on Dr. Bildsten's decision-making, it would simply have made his training more
4 complete.⁵⁶⁸

5 ISI's discussion of decisions from other jurisdictions holding that medical product
6 representatives are not liable for medical malpractice is similarly beside the point. ISI is not being
7 sued for not exercising proper medical judgment in the operating room. It is being sued because it
8 undertook to train Dr. Bildsten (or warn and instruct him) and it did so negligently.

9 **H. Mrs. Taylor Is Not Making A Separate Claim Against ISI Regarding the**
10 **Operating Table, Although its Advice Regarding the Table Is Evidence of the**
11 **Extent of its Partnership with Harrison**

12 ISI argues that it has no liability for any claims relating to the operating room table used
13 during Mr. Taylor's operation. Mrs. Taylor is not bringing a separate claim regarding the
14 operating table. But ISI's assertion that it does not make recommendations to hospitals regarding
15 tables is incorrect. In fact, after ISI represented that it would "partner" with Harrison in its
16 development of a robotic surgery practice, Harrison's da Vinci Task Force wanted to "assure table
17 selected can better accommodate obese patients."⁵⁶⁹ Harrison followed up by asking ISI's Dave
18 Carson regarding table choice,⁵⁷⁰ and he responded that "any table will work."⁵⁷¹ Damon Daniels,

19 ⁵⁶⁸ There are also important differences between a pharmacist and ISI. As ISI points out in its
20 brief, part of the Supreme Court's concern in *Mckee* was that imposing a duty on pharmacists
21 would cause them to second guess numerous prescriptions to avoid liability, placing an undue
22 burden on pharmacists and creating an antagonistic relationship between pharmacists and
23 physicians. 113 Wn.2d at 716, 782 P.2d at 1053. Here, however, ISI's representative Daniels
and Dr. Bildsten were in the same room for many hours, and Daniels was there precisely to
assist and advise the doctor. As he was there to communicate with the doctor, there is no reason
to believe that such communications would be burdensome, disruptive, or antagonistic.

⁵⁶⁹ PT-82, at 2.

⁵⁷⁰ PT-186.


⁵⁷¹ PT-187.

1 a recipient of the email, conceded at his deposition that he interpreted this as “a recommendation
2 that any table will work with the da Vinci.”⁵⁷² While this does not constitute a separate claim, it is
3 evidence of Harrison’s reliance on ISI, ISI’s knowledge of that reliance, and ISI’s partnership with
4 Harrison. As ISI told Harrison: “The success of your implementation is a direct reflection of
5 our effectiveness and our support.”⁵⁷³ The inability of the ISI-trained operating staff to place
6 Mr. Taylor in the proper surgical position, even with the help of Daniels, is evidence of the
7 poor training and inadequate warnings that caused Mr. Taylor’s disastrous outcome.

8
9 V. CONCLUSION

10 To be sure, there are many arguments ISI can make in an attempt to avoid liability in this
11 case. Just as surely, all of those arguments require resolution of factual disputes in its
12 favor. Ultimately, that may be the ultimate result in this case. But at this stage the Court must
13 view all the facts and inferences in the light most favorable to plaintiffs. Such an analysis requires
14 that ISI’s motions for summary judgment be denied.

15 DATED this 25 day of January, 2013.

16
17 
18 Richard H. Friedman, WSBA # 30626

19 FRIEDMAN | RUBIN
20 1126 Highland Ave.
21 Bremerton, WA 98337
22 Telephone: (360) 782-4300
E-mail: rfriedman@friedmanrubin.com

23 ⁵⁷² Exhibit A to Mullenix Declaration (Daniels Deposition) at 220:22-221:2.

⁵⁷³ PT-72 at 8.

1 **CERTIFICATE OF SERVICE**

2 I hereby certify that on 1/25, 2013, that a copy of the foregoing document was
3 hand delivered for filing with the Superior Court, Kitsap County with a copy e-mailed and
4 mailed, via First Class Mail, to the following:

5 Jeffrey R. Johnson, Esq.
6 Scheer & Zehnder, LLP
7 701 Pike Street, Suite 2200
8 Seattle, WA 98101

9 *Attorneys for Defendant Intuitive Surgical Inc.*

10 And a copy mailed to the following:

11 Allen J. Ruby
12 Skadden, Arps, Slate, Meagher & Flom
13 525 University Ave.
14 Palo Alto, CA 94301

15 *Attorneys for Defendant Intuitive Surgical Inc.*

16 Dated this 25th day of January, 2013.

17 _____
18 Dana C. Watkins